Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
37 "Won Seog Kim"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
More +
Original Articles
Hematologic malignancy
Clinical Impact of Microbiome Characteristics in Treatment-Naïve Extranodal NK/T-Cell Lymphoma Patients
Sang Eun Yoon, Woorim Kang, Junhun Cho, Mauricio Chalita, Je Hee Lee, Dong-Wook Hyun, Hyun Kim, Seok Jin Kim, Won Seog Kim
Cancer Res Treat. 2025;57(2):597-611.   Published online August 16, 2024
DOI: https://doi.org/10.4143/crt.2024.675
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Extranodal natural killer/T-cell lymphoma (ENKTL) predominantly manifests in East Asia and Latin America. Despite shared intrinsic factors, such as ethnic and genetic backgrounds, the progression of ENKTL can be influenced by extrinsic factors related to changing lifestyle patterns.
Materials and Methods
This study collected stool samples from newly diagnosed (ND)–ENKTL patients (n=40) and conducted whole genome shotgun sequencing.
Results
ND-ENKTL revealed reduced alpha diversity in ND-ENKTL compared to healthy controls (HCs) (p=0.008), with Enterobacteriaceae abundance significantly contributing to the beta diversity difference between ENKTL and HCs (p < 0.001). Functional analysis indicated upregulated aerobic metabolism and degradation of aromatic compounds in ND-ENKTL. Enterobacteriaceae were associated not only with clinical data explaining disease status (serum C-reactive protein, stage, prognosis index of natural killer cell lymphoma [PINK], and PINK-E) but also with clinical outcomes (early relapse and short progression-free survival). The relative abundance of Enterobacteriaceae at the family level was similar between ENKTL and diffuse large B-cell lymphoma (DLBCL) (p=0.140). However, the ENKTL exhibited a higher abundance of Escherichia, in contrast to the prevalence of Enterobacter and Citrobacter in DLBCL. Linear regression analysis demonstrated a significant association between Escherichia abundance and programmed cell death-ligand-1 (PD-L1) levels in tissue samples (p=0.025), whereas no correlation with PD-L1 was observed for Enterobacteriaceae at the family level (p=0.571).
Conclusion
ND-ENKTL exhibited an abundance of Enterobacteriaceae and a dominant presence of Escherichia. These microbial characteristics correlated with disease status, treatment outcomes, and PD-L1 expression, suggesting the potential of the ENKTL microbiome as a biomarker and cause of lymphomagenesis, which warrants further exploration.
  • 1,133 View
  • 104 Download
Close layer
Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study
Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin, Hyeon-Seok Eom, Dok Hyun Yoon, Hong Ghi Lee, Seong Hyun Jeong, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2025;57(1):267-279.   Published online July 16, 2024
DOI: https://doi.org/10.4143/crt.2024.479
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.
Materials and Methods
Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.
Results
Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.
Conclusion
This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.
  • 1,999 View
  • 156 Download
Close layer
Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2024;56(3):920-935.   Published online January 16, 2024
DOI: https://doi.org/10.4143/crt.2023.869
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.
Materials and Methods
We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.
Results
Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.
Conclusion
Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.

Citations

Citations to this article as recorded by  
  • Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
    Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
    Annals of Laboratory Medicine.2025; 45(1): 90.     CrossRef
  • Circulating tumor DNA in lymphoma: technologies and applications
    Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
    Journal of Hematology & Oncology.2025;[Epub]     CrossRef
  • Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
    Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
    Blood Reviews.2024; 68: 101237.     CrossRef
  • Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review
    Marie Hairing Enemark, Jonas Klejs Hemmingsen, Maja Lund Jensen, Robert Kridel, Maja Ludvigsen
    International Journal of Molecular Sciences.2024; 25(20): 11179.     CrossRef
  • 3,473 View
  • 173 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon, Jae-Yong Kwak, Chul Won Choi, Min Kyoung Kim, Sung Young Oh, Hye Jin Kang, Seung Hyun Nam, Hyeok Shim, Joon Seong Park, Yeung-Chul Mun, Cheolwon Suh, the Korean Society of Hematology Lymphoma Working Party
Cancer Res Treat. 2023;55(4):1355-1362.   Published online March 30, 2023
DOI: https://doi.org/10.4143/crt.2023.271
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL).
Materials and Methods
Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy.
Results
Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent grade 3 adverse events (40.0%) and 5 treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016).
Conclusion
Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients. ClinicalTrials.gov ID: NCT01054781.
  • 4,849 View
  • 262 Download
Close layer
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis
Jinchul Kim, Jinhyun Cho, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2023;55(3):1031-1047.   Published online March 13, 2023
DOI: https://doi.org/10.4143/crt.2022.1658
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.
Materials and Methods
R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.
Results
Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.
Conclusion
Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.

Citations

Citations to this article as recorded by  
  • Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jean L. Koff, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Michele Stanchina, Sara Haddadi, Carla Casulo, Sabarish Ayyapp
    Clinical Lymphoma Myeloma and Leukemia.2025; 25(4): e183.     CrossRef
  • Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis
    Hanzala Ahmed Farooqi, Muhammad Saffi Ullah, Ahmed Raza, Zain Sadiq, Wardah Ali Shaikh, Rahmah Muhammad, Muhammad Shoaib Hussain
    Critical Reviews in Oncology/Hematology.2025; 207: 104611.     CrossRef
  • Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma
    Abdur Jamil, Zaheer Qureshi, Rimsha Siddique, Faryal Altaf, Hamzah Akram, Rohma Jamil, Shehroz Aslam, Insija I. Selene
    American Journal of Clinical Oncology.2025;[Epub]     CrossRef
  • Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
    Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
    Discover Oncology.2025;[Epub]     CrossRef
  • Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
    Xin-Zhuo Zhan, Yi-Wen Bo, Yu Zhang, Hai-Dong Zhang, Zhi-Hao Shang, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Wan-Zhou Zhao, Timo Teimonen, Tao Liu, Meng-Yi Lu, Ye Yang, Shan-Liang Sun, Hai-Wen Ni
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol
    Mohammadreza Eslami, Mahdi Mehrabi, Mehrdad Payandeh, Fakhredin Saba, Chen Li
    PLOS ONE.2024; 19(8): e0308247.     CrossRef
  • Clinical scoring systems, molecular subtypes and baseline [18F]FDG PET/CT image analysis for prognosis of diffuse large B-cell lymphoma
    Zhuxu Sun, Tianshuo Yang, Chongyang Ding, Yuye Shi, Luyi Cheng, Qingshen Jia, Weijing Tao
    Cancer Imaging.2024;[Epub]     CrossRef
  • Targeting CD22 for B-cell hematologic malignancies
    Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
    Experimental Hematology & Oncology.2023;[Epub]     CrossRef
  • 8,120 View
  • 675 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(2):684-692.   Published online January 2, 2023
DOI: https://doi.org/10.4143/crt.2022.1434
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by  
  • Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
    Journal of Cancer Research Updates.2024; 13: 1.     CrossRef
  • Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
    L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
    Bone Marrow Transplantation.2024; 59(6): 838.     CrossRef
  • Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
    Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
    Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
    Clinical and Experimental Medicine.2023; 23(8): 4219.     CrossRef
  • 5,624 View
  • 207 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(1):325-333.   Published online April 22, 2022
DOI: https://doi.org/10.4143/crt.2022.008
AbstractAbstract PDFPubReaderePub
Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by  
  • PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
    Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
    Cancer Cell International.2025;[Epub]     CrossRef
  • Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
    Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
    Discover Oncology.2025;[Epub]     CrossRef
  • Recent advances in cellular immunotherapy for lymphoid malignancies
    Haerim Chung, Hyunsoo Cho
    Blood Research.2023; 58(4): 166.     CrossRef
  • Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
    Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
    Biomedicine & Pharmacotherapy.2022; 153: 113341.     CrossRef
  • 7,788 View
  • 358 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK
Sora Kang, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Yoon Sei Lee, Chan-Sik Park, Heounjeong Go, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Seok Jin Kim, Won Seog Kim, Sang Eun Yoon, Young Hyeh Ko, Cheolwon Suh
Cancer Res Treat. 2023;55(1):314-324.   Published online March 31, 2022
DOI: https://doi.org/10.4143/crt.2022.015
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.
Materials and Methods
A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).
Results
The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.
Conclusion
Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.

Citations

Citations to this article as recorded by  
  • Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma
    Yun Hui, Yingjun Gao, Jiawei Li, Qingtao Kong, Yuanyuan Duan, Haibo Liu, Fang Liu, Hong Sang
    Annals of Hematology.2024; 103(4): 1285.     CrossRef
  • Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
    Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantin
    Cancers.2024; 16(2): 238.     CrossRef
  • Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
    Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
    Korean Journal of Radiology.2024; 25(2): 189.     CrossRef
  • A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase
    Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang
    Future Oncology.2024; 20(28): 2071.     CrossRef
  • 5,281 View
  • 132 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)
Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won
Cancer Res Treat. 2023;55(1):304-313.   Published online March 30, 2022
DOI: https://doi.org/10.4143/crt.2022.004
AbstractAbstract PDFPubReaderePub
Purpose
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.
Materials and Methods
Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg/kg/day, intravenously) administered on days –7, –6, and –5, etoposide (400 mg/m2 intravenously) on days –5 and –4, and melphalan (50 mg/m2/day intravenously) on days –3 and –2. The BuCE regimen was comprised of busulfan (3.2 mg/kg/day intravenously) on days –7, –6, and –5, etoposide (400 mg/m2/day intravenously) on days –5 and –4, and cyclophosphamide (50 mg/kg/day intravenously) on days –3 and –2. The primary endpoint was 2-year progression-free survival (PFS).
Results
Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.
Conclusion
There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.

Citations

Citations to this article as recorded by  
  • Shorting of existing conditioning regimen for relapsed/refractory gastric diffuse large B-cell lymphoma transplant and studying its related outcomes: A first of its kind case report
    Priyatesh Chandra Dwivedi, Yasam Venkata Ramesh, Raj Nagarkar
    Iraqi Journal of Hematology.2025;[Epub]     CrossRef
  • CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-match
    Tao Wang, Ping Liu, Lili Xu, Lei Gao, Xiong Ni, Gusheng Tang, Li Chen, Jie Chen, Libing Wang, Yang Wang, Weijia Fu, Wenqin Yue, Na Liu, Ruobing Li, Guihua Lu, Yanrong Luo, Jianmin Yang
    Annals of Hematology.2024; 103(2): 575.     CrossRef
  • 6,055 View
  • 236 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
Seok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, Kyung Ju Ryu, Bon Park, Donghyun Park, Duck Cho, Hyun-Young Kim, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Won Seog Kim
Cancer Res Treat. 2023;55(1):291-303.   Published online March 2, 2022
DOI: https://doi.org/10.4143/crt.2022.017
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).
Materials and Methods
After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.
Results
Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.
Conclusion
Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.

Citations

Citations to this article as recorded by  
  • Clinical use of circulating tumor DNA analysis in patients with lymphoma
    Bettina Bisig, Karine Lefort, Sylvain Carras, Laurence de Leval
    Human Pathology.2025; 156: 105679.     CrossRef
  • Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
    Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
    Annals of Laboratory Medicine.2025; 45(1): 90.     CrossRef
  • Circulating tumor DNA in lymphoma: technologies and applications
    Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
    Journal of Hematology & Oncology.2025;[Epub]     CrossRef
  • Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application
    Zongyao Huang, Yao Fu, Hong Yang, Yehan Zhou, Min Shi, Qingyun Li, Weiping Liu, Junheng Liang, Liuqing Zhu, Sheng Qin, Huangming Hong, Yang Liu
    Molecular Cancer.2024;[Epub]     CrossRef
  • Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
    Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim
    Cancer Research and Treatment.2024; 56(3): 920.     CrossRef
  • Minimal residual disease detection in lymphoma: methods, procedures and clinical significance
    Sijun Zhang, Xiangyu Wang, Zhenzhen Yang, Mengjie Ding, Mingzhi Zhang, Ken H. Young, Xudong Zhang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
    Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
    Blood Reviews.2024; 68: 101237.     CrossRef
  • A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas
    Laurence de Leval, Philippe Gaulard, Ahmet Dogan
    Blood.2024; 144(18): 1855.     CrossRef
  • In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas
    Jin Ju Kim, Hyun-Young Kim, Zisun Choi, So yoon Hwang, Hansol Jeong, Jong Rak Choi, Sang Eun Yoon, Won Seog Kim, Sun-Hee Kim, Hee-Jin Kim, Sang-Yong Shin, Seung-Tae Lee, Seok Jin Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Circulating tumor DNA in NK/T and peripheral T cell lymphoma
    Yu-Jia Huo, Wei-Li Zhao
    Seminars in Hematology.2023; 60(3): 173.     CrossRef
  • A genetic profiling guideline to support diagnosis and clinical management of lymphomas
    Margarita Sánchez-Beato, Miriam Méndez, María Guirado, Lucía Pedrosa, Silvia Sequero, Natalia Yanguas-Casás, Luis de la Cruz-Merino, Laura Gálvez, Marta Llanos, Juan Fernando García, Mariano Provencio
    Clinical and Translational Oncology.2023; 26(5): 1043.     CrossRef
  • 6,959 View
  • 296 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2022;54(4):1268-1277.   Published online December 30, 2021
DOI: https://doi.org/10.4143/crt.2021.1168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.
  • 7,981 View
  • 299 Download
  • 1 Web of Science
Close layer
Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
Sang Eun Yoon, Yeon Jeong Kim, Joon Ho Shim, Donghyun Park, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Yeung-Chul Mun, Kyoung Eun Lee, Duck Cho, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2022;54(2):597-612.   Published online July 23, 2021
DOI: https://doi.org/10.4143/crt.2021.752
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL.
Materials and Methods
Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018.
Results
Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment.
Conclusion
The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.

Citations

Citations to this article as recorded by  
  • Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
    Seok Jin Kim, Jin Ju Kim, Mi Ri Park, Bon Park, Kyung Ju Ryu, Sang Eun Yoon, Won Seog Kim, Saeam Shin, Seung-Tae Lee
    Annals of Laboratory Medicine.2025; 45(1): 90.     CrossRef
  • Circulating tumor DNA in lymphoma: technologies and applications
    Lina Fu, Xuerong Zhou, Xiaoyu Zhang, Xuhua Li, Fan Zhang, Hongcang Gu, Xiaoxue Wang
    Journal of Hematology & Oncology.2025;[Epub]     CrossRef
  • Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
    Yujie Zhong, Geok Wee Tan, Johanna Bult, Nick Veltmaat, Wouter Plattel, Joost Kluiver, Roelien Enting, Arjan Diepstra, Anke van den Berg, Marcel Nijland
    BMC Cancer.2024;[Epub]     CrossRef
  • Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma
    Jin-Hua Liang, Yi-Fan Wu, Hao-Rui Shen, Yue Li, Jun-Heng Liang, Rui Gao, Wei Hua, Chun-Yu Shang, Kai-Xin Du, Tong-Yao Xing, Xin-Yu Zhang, Chen-Xuan Wang, Liu-Qing Zhu, Yang W. Shao, Jian-Yong Li, Jia-Zhu Wu, Hua Yin, Li Wang, Wei Xu
    Leukemia.2024; 38(7): 1541.     CrossRef
  • Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review
    Lakshmi Nayak, Chetan Bettegowda, Florian Scherer, Norbert Galldiks, Manmeet Ahluwalia, Alexander Baraniskin, Louisa von Baumgarten, Jacoline E C Bromberg, Andrés J M Ferreri, Christian Grommes, Khê Hoang-Xuan, Julia Kühn, James L Rubenstein, Roberta Rudà
    Neuro-Oncology.2024; 26(6): 993.     CrossRef
  • Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
    Sang Eun Yoon, Seung-Ho Shin, Dae Keun Nam, Junhun Cho, Won Seog Kim, Seok Jin Kim
    Cancer Research and Treatment.2024; 56(3): 920.     CrossRef
  • Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future
    Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
    Blood Reviews.2024; 68: 101237.     CrossRef
  • Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas
    Jurik A. Mutter, Stefan K. Alig, Mohammad S. Esfahani, Eliza M. Lauer, Jan Mitschke, David M. Kurtz, Julia Kühn, Sabine Bleul, Mari Olsen, Chih Long Liu, Michael C. Jin, Charles W. Macaulay, Nicolas Neidert, Timo Volk, Michel Eisenblaetter, Sebastian Raue
    Journal of Clinical Oncology.2023; 41(9): 1684.     CrossRef
  • Clinical applications of circulating tumor DNA in central nervous system lymphoma
    Anna Katharina Foerster, Eliza M. Lauer, Florian Scherer
    Seminars in Hematology.2023; 60(3): 150.     CrossRef
  • Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease
    Gloria Figaredo, Alejandro Martín-Muñoz, Santiago Barrio, Laura Parrilla, Yolanda Campos-Martín, María Poza, Laura Rufián, Patrocinio Algara, Marina De La Torre, Ana Jiménez Ubieto, Joaquín Martínez-López, Luis-Felipe Casado, Manuela Mollejo
    Cancers.2023; 15(16): 4022.     CrossRef
  • Asian variant intravascular large B-cell lymphoma with highly suspected central nervous system involvement: A case report
    Yong-Pyo Lee, Seung-Myoung Son, Jihyun Kwon
    World Journal of Clinical Cases.2023; 11(33): 8058.     CrossRef
  • The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies
    Rafael Colmenares, Noemí Álvarez, Santiago Barrio, Joaquín Martínez-López, Rosa Ayala
    Cancers.2022; 14(5): 1310.     CrossRef
  • 8,394 View
  • 299 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Hematologic Malignancy
Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels
Hyung-Don Kim, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Dok-Hyun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh
Cancer Res Treat. 2021;53(3):847-856.   Published online December 17, 2020
DOI: https://doi.org/10.4143/crt.2020.1060
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.
Materials and Methods
A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).
Results
The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum β2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum β2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum β2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.
Conclusion
Serum β2-microglobulin level is an independent prognostic factor for BL patients. The proposed β2-microglobulin–based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.

Citations

Citations to this article as recorded by  
  • Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review
    Aythami de Armas‐Castellano, Diego Infante‐Ventura, Tasmania del Pino‐Sedeño, Yadira González Hernández, Raul Quiros, Beatriz León‐Salas, Vincent Ribrag, María M. Trujillo‐Martín
    Cancer Medicine.2025;[Epub]     CrossRef
  • Predictive Value of Serum β2-Microglobulin for 28-Day Mortality in Sepsis Patients in the Emergency Department
    Xiangqun Zhang, Long Yang, Yu Gu, Junyuan Wu, Xue Mei, Shubin Guo
    Infection and Drug Resistance.2025; Volume 18: 2365.     CrossRef
  • The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients
    Ze Jin, Yi Miao, Jie Zhang, Jing Zhang, Chunling Wang, Xuzhang Lu, Yuqing Miao, Miao Sun, Yunping Zhang, Yun Zhuang, Haiwen Ni, Jingyan Xu, Wanchuan Zhuang, Min Zhao, Jianfeng Zhu, Min Xu, Guoqiang Lin, Haiying Hua, Xiaoyan Xie, Maozhong Xu, Tao Jia, Liji
    Annals of Hematology.2024; 103(7): 2257.     CrossRef
  • Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
    Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
    Korean Journal of Radiology.2024; 25(2): 189.     CrossRef
  • The Role of Beta2-Microglobulin in Central Nervous System Disease
    Zhen-Yuan Liu, Feng Tang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
    Cellular and Molecular Neurobiology.2024;[Epub]     CrossRef
  • Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study
    Zhen-Yuan Liu, Feng Tang, Jing Wang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
    BMC Cancer.2024;[Epub]     CrossRef
  • Serum beta2-microglobulin and peripheral blood eosinophils for the assessment of severity and prognosis with omicron variant COVID-19 infection
    Jie Tan, Hanxi Fang, Xiao Hu, Ming Yue, Junling Yang
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis
    Zhentian Wu, Chenyi Wang, Yao Lyu, Zheshen Lin, Ming Lu, Shixiong Wang, Bingxuan Wang, Na Yang, Yeye Li, Jianhong Wang, Xiaohui Duan, Na Zhang, Jing Gao, Yuan Zhang, Miaowang Hao, Zhe Wang, Guangxun Gao, Rong Liang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma
    Ning-Chun Chen, Hung Chang, Hsiao-Wen Kao, Che-Wei Ou, Ming-Chung Kuo, Po-Nan Wang, Tung-Liang Lin, Jin-Hou Wu, Yu-Shin Hung, Yi-Jiun Su, Yuen-Chin Ong, Hsuan-Jen Shih
    Clinical and Experimental Medicine.2023; 23(7): 3759.     CrossRef
  • Tuberculosis combined with Burkitt lymphoma in a kidney transplant recipient: A case report and literature review
    Jian-Nan Hu, Mu-Qing Yu, Li-Juan Hua, Chen Bao, Qian Liu, Chao Liu, Zi-Ling Li, Xi Wang, Shu-Yun Xu
    Medicine.2023; 102(18): e33671.     CrossRef
  • Elevated serum beta-2 microglobulin level predicts short-term poor prognosis of patients with de novo acute omicron variant COVID-19 infection
    Shengping Gong, Ruishuang Ma, Ting Zhu, Xiaoqin Ge, Rongrong Xie, Qingsong Tao, Cong Shi
    Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
  • An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers
    Yajiao Liu, Li Sheng, Haiying Hua, Jingfen Zhou, Ying Zhao, Bei Wang
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified
    Hyung-Don Kim, Hyungwoo Cho, Byeong Seok Sohn, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh
    Leukemia & Lymphoma.2022; 63(1): 124.     CrossRef
  • 6,253 View
  • 151 Download
  • 12 Web of Science
  • 13 Crossref
Close layer
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2020;52(2):374-387.   Published online August 13, 2019
DOI: https://doi.org/10.4143/crt.2019.198
AbstractAbstract PDFPubReaderePub
Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15).
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

Citations

Citations to this article as recorded by  
  • Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
    Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
    Current Cancer Therapy Reviews.2024; 20(1): 53.     CrossRef
  • Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma
    Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami,
    The Journal of Dermatology.2024; 51(8): 1037.     CrossRef
  • Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review
    Jiewen Tan, Jinman Zhong, Wanzhen Hu, Guobiao Wu, Chong Zeng, Dan Xiong
    Journal of International Medical Research.2024;[Epub]     CrossRef
  • Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
    Roxanne C. Jewell, Richard J. Mills, Colm Farrell, Sandra A. G. Visser
    British Journal of Clinical Pharmacology.2024;[Epub]     CrossRef
  • Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
    Chengji Wang, Liang Wang
    Chinese Medical Journal.2024; 137(19): 2308.     CrossRef
  • Research progress on EBV-associated NK/T cell lymphoma
    Jun CAI, Yi CAO, LiYun QIU, Yan GAO, HuiQiang HUANG, QingQing CAI
    SCIENTIA SINICA Vitae.2024; 54(12): 2363.     CrossRef
  • Treatment of extranodal NK/T-cell lymphoma: From past to future
    Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
    Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
    Cancers.2023; 15(5): 1366.     CrossRef
  • Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
    Susan Y. Wu, Penny Q. Fang, Ethan B. Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E. Malpica Castillo, Ranjit Nair, Raphael E. Steiner, Paolo Strati, Auris O. Huen, Swaminathan P. Iyer, Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunthe
    Advances in Radiation Oncology.2023; 8(6): 101279.     CrossRef
  • Novel target and treatment agents for natural killer/T-cell lymphoma
    Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
    Journal of Hematology & Oncology.2023;[Epub]     CrossRef
  • Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis
    Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu, Jiuda Zhao
    Cancer Innovation.2023; 2(5): 346.     CrossRef
  • Advances and challenges of immunotherapies in NK/T cell lymphomas
    Ling He, Na Chen, Lei Dai, Xingchen Peng
    iScience.2023; 26(11): 108192.     CrossRef
  • Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
    Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang
    Cancer Medicine.2023; 12(24): 21725.     CrossRef
  • A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
    Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
    Blood Research.2023; 58(4): 194.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
    Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcu
    Blood.2022; 139(13): 1999.     CrossRef
  • Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
    Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas, Theodoros P. Vassilakopoulos
    Cancers.2022; 14(8): 1917.     CrossRef
  • Basic immunohistochemistry for lymphoma diagnosis
    Junhun Cho
    Blood Research.2022; 57(S1): S55.     CrossRef
  • Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
    John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
    Journal of Clinical Medicine.2022; 11(10): 2699.     CrossRef
  • CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report
    Kashif Osmani, Eshana Shah, Bradley Drumheller, Shaun Webb, Manmeet Singh, Paul Rubinstein, John Patrick Galvin, Megan S. Lim, Carlos Murga-Zamalloa
    Diagnostic Pathology.2022;[Epub]     CrossRef
  • EBV-associated NK and T-cell lymphoid neoplasms
    Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim
    Current Opinion in Oncology.2022; 34(5): 422.     CrossRef
  • Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
    Magda Zanelli, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, Saverio Pancetti, Giovanni Martino, Giuseppe Broggi, Rosario Caltabiano, Alberto
    Cancers.2022; 14(21): 5458.     CrossRef
  • Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
    Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
    Seminars in Hematology.2022; 59(4): 198.     CrossRef
  • Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
    Huan Chen, Tao Pan, Yizi He, Ruolan Zeng, Yajun Li, Liming Yi, Hui Zang, Siwei Chen, Qintong Duan, Ling Xiao, Hui Zhou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • NK-/T-cell lymphomas
    Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
    Leukemia.2021; 35(9): 2460.     CrossRef
  • The landscape of new drugs in extranodal NK/T-cell lymphoma
    Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang
    Cancer Treatment Reviews.2020; 89: 102065.     CrossRef
  • Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
    Caiqin Xie, Xian Li, Hui Zeng, Wenbin Qian
    Experimental Hematology & Oncology.2020;[Epub]     CrossRef
  • New agents and regimens for diffuse large B cell lymphoma
    Liang Wang, Lin-rong Li, Ken H. Young
    Journal of Hematology & Oncology.2020;[Epub]     CrossRef
  • A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas
    Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • 10,477 View
  • 634 Download
  • 29 Web of Science
  • 29 Crossref
Close layer
Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh, On behalf of the Consortium for Improving Survival of Lymphoma investigators
Cancer Res Treat. 2019;51(4):1302-1312.   Published online February 14, 2019
DOI: https://doi.org/10.4143/crt.2018.555
AbstractAbstract PDFPubReaderePub
Purpose
Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.
Materials and Methods
We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.
Results
Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.
Conclusion
PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

Citations

Citations to this article as recorded by  
  • Space-associated lymphomas: review of a heterogeneous group of old and new entities
    Judith A Ferry
    Diagnostic Histopathology.2024; 30(8): 430.     CrossRef
  • A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients
    Julien Calvani, Laurence Gérard, Jehane Fadlallah, Elsa Poullot, Lionel Galicier, Cyrielle Robe, Margaux Garzaro, Remi Bertinchamp, David Boutboul, Wendy Cuccuini, Jean-Michel Cayuela, Philippe Gaulard, Éric Oksenhendler, Véronique Meignin
    American Journal of Surgical Pathology.2022; 46(3): 353.     CrossRef
  • A Rapidly Accumulating Effusion in an Immunocompetent Woman
    Zein Kattih, Akhilesh Mahajan, Morana Vojnic, Jordan Steinberg, Alyssa Yurovitsky, Jin Ah Kim, Amory Novoselac
    Chest.2022; 161(6): e377.     CrossRef
  • Human herpesvirus‐8–positive primary effusion lymphoma in HIV‐negative patients: Single institution case series with a multidisciplinary characterization
    Giovanni Rossi, Ilaria Cozzi, Irene Della Starza, Lucia Anna De Novi, Maria Stefania De Propris, Aurelia Gaeta, Luigi Petrucci, Alessandro Pulsoni, Federica Pulvirenti, Valeria Ascoli
    Cancer Cytopathology.2021; 129(1): 62.     CrossRef
  • Primary effusion lymphoma in human immune deficiency (HIV)‐negative non‐organ transplant immunocompetent patients
    Lisi Yuan, James R. Cook, Tarik M. Elsheikh
    Diagnostic Cytopathology.2020; 48(4): 380.     CrossRef
  • Clinicopathologic characteristics and survival of patients with primary effusion lymphoma
    Cristian Aguilar, Caddie Laberiano, Brady Beltran, Cecilia Diaz, Alvaro Taype-Rondan, Jorge J. Castillo
    Leukemia & Lymphoma.2020; 61(9): 2093.     CrossRef
  • 6,943 View
  • 159 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim, Jiyeon Hyeon, Inju Cho, Young Hyeh Ko, Won Seog Kim
Cancer Res Treat. 2019;51(2):611-622.   Published online July 20, 2018
DOI: https://doi.org/10.4143/crt.2018.191
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), realworld data about the efficacy of pembrolizumab in NHL patients are limited.
Materials and methods
We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)‒positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression.
Results
Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%).
Conclusion
Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.

Citations

Citations to this article as recorded by  
  • Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial
    Kaiyang Ding, Hailing Liu, Lixia Sheng, Jie Ma, Xiaohui Zhang, Hongming Huang, Wei Shi, Hongling Peng, Lei Cao, Wei Wu, Jianyong Li, Lei Fan
    European Journal of Cancer.2025; 214: 115155.     CrossRef
  • MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma
    Kyung Ju Ryu, Haein Ji, Bon Park, Sang Eun Yoon, Junhun Cho, Won Seog Kim, Hyeon Ho Kim, Seok Jin Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Tislelizumab and Radiation Therapy in Low-Risk Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Phase II Study Protocol
    Jia-Ying Li, Shu-Nan Qi, Chen Hu, Xin Liu, Yong Yang, Tao Wu, Rong Zheng, Xiao-Li Feng, Xiao-Guang Ni, Feng-Yan Jin, Yu-Qin Song, Wei-Ping Liu, Sheng-Yu Zhou, Ye-Xiong Li
    Future Oncology.2024; 20(5): 245.     CrossRef
  • Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
    Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
    Current Cancer Therapy Reviews.2024; 20(1): 53.     CrossRef
  • The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents
    Upton D. Allen, Arnaud G. L'Huillier, Catherine M. Bollard, Thomas G. Gross, Robert J. Hayashi, Britta Höcker, Britta Maecker‐Kolhoff, Stephen D. Marks, George Vincent Mazariegos, Francoise Smets, Ralf U. Trappe, Gary Visner, Richard E. Chinnock, Patrizia
    Pediatric Transplantation.2024;[Epub]     CrossRef
  • Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
    Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
    Cancer Research and Treatment.2024; 56(2): 681.     CrossRef
  • Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
    Wendy W. L. Lee, Jing Quan Lim, Tiffany P. L. Tang, Daryl Tan, Ser Mei Koh, Kia Joo Puan, Liang Wei Wang, Jackwee Lim, Kim Peng Tan, Wee Joo Chng, Soon Thye Lim, Choon Kiat Ong, Olaf Rotzschke
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art
    Magda Zanelli, Valentina Fragliasso, Paola Parente, Alessandra Bisagni, Francesca Sanguedolce, Maurizio Zizzo, Giuseppe Broggi, Stefano Ricci, Andrea Palicelli, Moira Foroni, Fabrizio Gozzi, Pietro Gentile, Andrea Morini, Nektarios Koufopoulos, Rosario Ca
    International Journal of Molecular Sciences.2024; 25(12): 6447.     CrossRef
  • EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
    Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
    American Journal of Hematology.2024; 99(10): 2002.     CrossRef
  • Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
    Maryam Pourmaleki, Caitlin J. Jones, Sabrina D. Mellinghoff, Brian D. Greenstein, Priyadarshini Kumar, Miguel Foronda, Daniel A. Navarrete, Carl Campos, Mikhail Roshal, Nikolaus Schultz, Sohrab P. Shah, Andrea Schietinger, Nicholas D. Socci, Travis J. Hol
    Clinical Cancer Research.2024; 30(17): 3881.     CrossRef
  • PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis
    Youli Li, Yonghe Wu, Sufen Cao, Baohua Yu, Qunling Zhang, Zuguang Xia, Junning Cao, Fangfang Lv, Guang-Liang Chen
    Blood Research.2024;[Epub]     CrossRef
  • The ‘Oma’s of the Gammas—Cancerogenesis by γ-Herpesviruses
    Anwesha Banerjee, Debashree Dass, Soumik Mukherjee, Mollina Kaul, R. Harshithkumar, Parikshit Bagchi, Anupam Mukherjee
    Viruses.2024; 16(12): 1928.     CrossRef
  • A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
    Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Zachariah DeFilipp, Alex F. Herrera, David C. Fisher, Ann S. LaCasce, Oreofe O. Odejide, Samuel Y. Ng, Caron A. Jacobson, Reid W. Merryman, Austin I. Kim, Yago L. Ni
    Blood.2023; 142(7): 621.     CrossRef
  • The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
    Yanxia He, Yan Gao, Liqin Ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhiming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan Liu, Huiqiang Huang
    Journal of Cancer Research and Clinical Oncology.2023; 149(5): 2017.     CrossRef
  • Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment
    Chunlan Zhang, Leiming Wang, Caigang Xu, Heng Xu, Yu Wu
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies
    Maria G. Desimio, Daniela A. Covino, Beatrice Rivalta, Caterina Cancrini, Margherita Doria
    Cancers.2023; 15(6): 1914.     CrossRef
  • Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
    Jie Zhou, Guanming Chen, Jiuling Wang, Bo Zhou, Xuemin Sun, Jinsong Wang, Shu Tang, Xiangju Xing, Xiaofei Hu, Yang Zhao, Yu Peng, Wenjiong Shi, Tingting Zhao, Yuzhang Wu, Hanbing Zhong, Ni Hong, Zhihua Ruan, Yi Zhang, Wenfei Jin
    Oncogenesis.2023;[Epub]     CrossRef
  • Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies
    Till Braun, Alexandra Schrader
    Cancers.2023; 15(9): 2532.     CrossRef
  • Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
    Sarah Perdikis-Prati, Semira Sheikh, Antonin Bouroumeau, Noémie Lang
    Biomedicines.2023; 11(6): 1720.     CrossRef
  • First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study
    Xiaoxiao Wang, Lei Wen, Jing Liao, Yanfen Feng, Yuhong Li, Zhaoming Zhou, Cheng Zhou, Huiqiang Huang
    British Journal of Haematology.2023; 202(4): 812.     CrossRef
  • Advances and challenges of immunotherapies in NK/T cell lymphomas
    Ling He, Na Chen, Lei Dai, Xingchen Peng
    iScience.2023; 26(11): 108192.     CrossRef
  • Adult's Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis: A case report
    Yi Sun, Han Yao, Xiaofeng Yu, Yunzhao Chen, Chen Chai
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Serious consequences of Epstein‐Barr virus infection: Hemophagocytic lymphohistocytosis
    Lingyue Xu, Xiaofang Guo, Hongzai Guan
    International Journal of Laboratory Hematology.2022; 44(1): 74.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers
    Alison Felipe Bordini Biggi, Deilson Elgui de Oliveira
    Biomolecules.2022; 12(3): 397.     CrossRef
  • Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
    Xi Chen, Wanchun Wu, Wenwen Wei, Liqun Zou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management
    Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
    American Journal of Hematology.2022; 97(7): 951.     CrossRef
  • Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
    John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
    Journal of Clinical Medicine.2022; 11(10): 2699.     CrossRef
  • Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders
    Susan Swee-Shan Hue, Siok-Bian Ng, Shi Wang, Soo-Yong Tan
    Cancers.2022; 14(10): 2483.     CrossRef
  • Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
    Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian
    Cancer Communications.2022; 42(6): 493.     CrossRef
  • Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
    N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell
    Journal for ImmunoTherapy of Cancer.2022; 10(6): e004984.     CrossRef
  • Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
    Felix Marsh-Wakefield, Angela L Ferguson, Ken Liu, Cositha Santhakumar, Geoffrey McCaughan, Umaimainthan Palendira
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
    Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
    Seminars in Hematology.2022; 59(4): 198.     CrossRef
  • Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
    Seok Jin Kim, Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Junhun Cho, Yoon Park, Won Seog Kim
    Cancers.2022; 14(22): 5618.     CrossRef
  • Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma
    Guang-Liang Chen, Zu-Guang Xia, Jia Jin, Bao-Hua Yu, Junning Cao, Amir Radfar
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
    Lee S. Nguyen, Lisa Raia, Bénédicte Lebrun-Vignes, Joe-Elie Salem
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience
    Yang Fu, Yue Zheng, Pei-Pei Wang, Yue-Yun Chen, Zhen-Yu Ding
    OncoTargets and Therapy.2021; Volume 14: 1073.     CrossRef
  • EBV et immunodépression
    Y. Dieudonne, M. Martin, A.-S. Korganow, D. Boutboul, A. Guffroy
    La Revue de Médecine Interne.2021; 42(12): 832.     CrossRef
  • PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
    Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane
    Cells.2021; 10(5): 1152.     CrossRef
  • NK-/T-cell lymphomas
    Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
    Leukemia.2021; 35(9): 2460.     CrossRef
  • The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment
    Emad Ababneh, Anas M Saad, Genevieve M Crane
    Histopathology.2021; 79(4): 451.     CrossRef
  • Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
    Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Cheolwon Suh, Felipe Suarez, John Radford, Lihua E. Budde, Jin Seok Kim, Emmanuel Bachy, H
    Annals of Hematology.2021; 100(10): 2529.     CrossRef
  • The Role of Epstein–Barr virus-encoded Latent Membrane Proteins in Host Immune Escape
    Yuanyuan Jiang, Yuan Ding, Shuzhen Liu, Bing Luo
    Future Virology.2021; 16(8): 565.     CrossRef
  • EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)
    Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, Maurizio Zizzo, Giovanni Martino, Cecilia Caprera, Valentina Fragliasso, Alessandra Soriano, Luca Valle, Stefano Ricci, Alberto Cavazza, Francesco Merli, Stefano A. Pileri, Stefano Ascani
    Cancers.2021; 13(18): 4578.     CrossRef
  • Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report
    Fatemeh Adabifirouzjaei, Bharam Khazai, Ghazaleh Azami, Ghazaleh Shoja-e-Razavi
    Journal of Medical Case Reports.2021;[Epub]     CrossRef
  • Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas
    Miriam Verdu-Bou, Gustavo Tapia, Agueda Hernandez-Rodriguez, Jose-Tomas Navarro
    Cancers.2021; 13(21): 5534.     CrossRef
  • Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
    Leila Sawada, Antonio Carlos Rosário Vallinoto, Igor Brasil-Costa
    Biomolecules.2021; 11(12): 1792.     CrossRef
  • Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
    Alejandro Olivares-Hernández, Luis Figuero-Pérez, José Pablo Miramontes-González, Álvaro López-Gutiérrez, Rogelio González-Sarmiento, Juan Jesús Cruz-Hernández, Emilio Fonseca-Sánchez
    Life.2021; 11(12): 1400.     CrossRef
  • EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management
    Brady E. Beltran, Denisse Castro, Sally Paredes, Roberto N. Miranda, Jorge J. Castillo
    American Journal of Hematology.2020; 95(4): 435.     CrossRef
  • Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
    Junhun Cho, Seok Jin Kim, Woong-Yang Park, Jinho Kim, Jeongmin Woo, Gahyun Kim, Sang Eun Yoon, Young Hyeh Ko, Won Seog Kim
    Modern Pathology.2020; 33(4): 603.     CrossRef
  • PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
    Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jenni
    Blood Advances.2020; 4(1): 122.     CrossRef
  • Checkmate for EBV-HLH
    Nader Kim El-Mallawany, Kenneth L. McClain
    Blood.2020; 135(11): 782.     CrossRef
  • CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
    Yue Song, Wei Song, Zhaoming Li, Wenting Song, Yibo Wen, Jiwei Li, Qingxin Xia, Mingzhi Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Stage IV natural killer/T-cell lymphoma with chronic active Epstein–Barr virus, treated with pembrolizumab and TCRαβ-depleted haploidentical hematopoietic stem cell transplantation
    Yeong Eun Kim, Hyery Kim, Juhee Shin, So Yoon Min, Sung Han Kang, Jin Kyung Suh, Kyung-Nam Koh, Ho Joon Im
    Leukemia & Lymphoma.2020; 61(9): 2250.     CrossRef
  • Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
    Sandhya Sharma, Wingchi K Leung, Helen E Heslop
    Current Stem Cell Reports.2020; 6(2): 17.     CrossRef
  • The roles of programmed death ligand 1 in virus-associated cancers
    Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
    Infection, Genetics and Evolution.2020; 84: 104368.     CrossRef
  • Immune-Checkpoint Blockade Therapy in Lymphoma
    Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami
    International Journal of Molecular Sciences.2020; 21(15): 5456.     CrossRef
  • Multiplex immunohistochemistry in lymphoma pathology: a research tool for study of the immune microenvironment
    Matthew Pugh, Ayse U. Akarka, Kelly Hunter, Stefan Dojcinov, Teresa Marafioti
    Diagnostic Histopathology.2020; 26(9): 407.     CrossRef
  • Targeting immune checkpoints in hematological malignancies
    Basit Salik, Mark J. Smyth, Kyohei Nakamura
    Journal of Hematology & Oncology.2020;[Epub]     CrossRef
  • Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
    Yonggang Pei, Josiah H. Y. Wong, Erle S. Robertson
    Cancers.2020; 12(9): 2565.     CrossRef
  • Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals
    Polina Shindiapina, Elshafa H. Ahmed, Anna Mozhenkova, Tamrat Abebe, Robert A. Baiocchi
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
    Ji-Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung
    International Journal of Molecular Sciences.2020; 21(21): 8000.     CrossRef
  • EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
    Danielle L.V. Maracaja, Vidya Puthenpura, Salley G. Pels, Dennis P. O’Malley, Jeffrey L. Sklar, Karin E. Finberg, Mina L. Xu
    Applied Immunohistochemistry & Molecular Morphology.2020; 28(10): 725.     CrossRef
  • Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
    Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener
    Vaccines.2020; 8(4): 708.     CrossRef
  • Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
    Zheng Yan, Shuna Yao, Yanyan Liu, Jianbo Zhang, Peng Li, Haiying Wang, Junfeng Chu, Shuang Zhao, Zhihua Yao
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
    Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, Junhun Cho, Sang Eun Yoon, Ji Young Lee, Kyung Ju Ryu, Young Hyeh Ko, Youngil Koh, Duck Cho, Soon Thye Lim, Marie Beck Enemark, Francesco D’Amore, Mette Bjerre, Choon Kiat Ong, Won Seog Kim
    Blood.2020; 136(24): 2754.     CrossRef
  • Pembrolizumab

    Reactions Weekly.2019; 1754(1): 273.     CrossRef
  • Immune checkpoint inhibitors in the treatment of virus-associated cancers
    Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma, Peng Wu
    Journal of Hematology & Oncology.2019;[Epub]     CrossRef
  • 13,954 View
  • 626 Download
  • 75 Web of Science
  • 68 Crossref
Close layer
Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
Hansang Lee, Dongryul Oh, Kyungmi Yang, Young Hyeh Ko, Yong Chan Ahn, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2019;51(2):547-555.   Published online July 10, 2018
DOI: https://doi.org/10.4143/crt.2018.190
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Duodenal-type follicular lymphoma (FL) is a rare variant of FL. There is still no consensus on the initial treatment, and clinical features including endoscopic findings are not familiar to most physicians. The objective of this study was to evaluate the outcome of patients who were initially treated with radiation therapy for duodenal-type FL.
Materials and Methods
We retrospectively analyzed 20 patients who were consecutively diagnosed with duodenaltype FL between 2008 and 2017. All patients received radiation therapywith curative intent.
Results
The median age of the patients was 52 years (range, 26 to 66 years), and females were predominant. Most patients (n=18, 90%) had stage I disease, and were diagnosed by a regular health examination in an asymptomatic state. The histological grade was one in 19 patients (95%), and the endoscopic findings were diffuse nodular (n=8), whitish granular (n=8), and mixed pattern (n=4). Radiation therapy was delivered to 17 patients with 24 Gy in 12 fractions, and to three patients with 30.6-36 Gy in 18 fractions. All patients were evaluated with endoscopy for response to radiation therapy, and complete response was achieved in 19 patients (95%). At the time of analysis, all patients survived without any evidence of late toxicities related with radiation therapy.
Conclusion
Taken together, radiation therapy alone could be effective in controlling duodenal lesion. A further study with longer follow-up duration is warranted to confirm our findings.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study
    Guilherme Duffles, Arthur Braga, Talita Silveira, Yana Novis, Celso Arrais, Luciana Tucunduva, Ana Rita Fonseca, Davimar Borducchi, Pedro Neffa, Fernando Blumm, Marianne de Castro Gonçalves, Frederico Moreira, Fabio Nucci, Eduardo Rego, Vanderson Rocha
    Leukemia & Lymphoma.2025; 66(1): 95.     CrossRef
  • Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation
    Jan Bosch-Schips, Xenia Parisi, Fina Climent, Francisco Vega
    Human Pathology.2025; 156: 105676.     CrossRef
  • The Role of Small Bowel Capsule Endoscopy in Determining the Treatment Strategy for Duodenal Follicular Lymphoma: A Single-Center Retrospective Study
    Donghoon Kang, Gi-June Min, Tong Yoon Kim, Young-Woo Jeon, Yukyung Cho, Jae Myung Park, Joo Hyun O, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho
    Diagnostics.2025; 15(2): 193.     CrossRef
  • Recent updates on treatment options for primary follicular lymphoma of the gastrointestinal tract
    Masaya Iwamuro, Takehiro Tanaka, Daisuke Ennishi, Motoyuki Otsuka
    Expert Review of Gastroenterology & Hepatology.2024; 18(7): 367.     CrossRef
  • Duodenal-type follicular lymphoma: comprehensive insights into disease characteristics and established treatment strategies
    Ahmed Alnughmush, Riad El Fakih, Ruah Alyamany, Nasir Bakshi, Saud Alhayli, Mahmoud Aljurf
    Current Opinion in Oncology.2024; 36(6): 577.     CrossRef
  • Duodenal Polyposis: An Incidental Finding of Duodenal-Type Follicular Lymphoma
    Rachael Hagen, Jasmine Tidwell, Emily Weng, Steven A Goldenberg, Anjiya Shaikh
    Cureus.2024;[Epub]     CrossRef
  • Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma
    Jong Yun Baek, Do Hoon Lim, Dongryul Oh, Heerim Nam, Jae J Kim, Jun Haeng Lee, Byung-Hoon Min, Hyuk Lee
    Cancer Research and Treatment.2022; 54(1): 294.     CrossRef
  • Duodenal Follicular Lymphoma: Track or Treat?
    M. Varanese, A. Lauro, I. Lattina, D. Tripodi, T. Daralioti, S. Khouzam, I. R. Marino, V. Stigliano, V. D’Andrea, S. Frattaroli, S. Sorrenti
    Digestive Diseases and Sciences.2022; 67(5): 1733.     CrossRef
  • Incidentally Found Mucosal Nodularity on the Second Portion of Duodenum
    Joo Hyun Lim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(2): 163.     CrossRef
  • Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis
    Makoto Saito, Akio Mori, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Hirokazu Sugino
    World Journal of Gastrointestinal Oncology.2022; 14(8): 1552.     CrossRef
  • Linfoma folicular duodenal primario: reporte de caso y revisión de la literatura
    Lázaro Antonio Arango Molano, Andrés Sánchez Gil, Ileana Rocío Bautista Parada
    Revista colombiana de Gastroenterología.2021; 36(4): 525.     CrossRef
  • What do we know about duodenal‐type follicular lymphoma? From pathological definition to treatment options
    Guilherme Duffles Amarante, Graham Collins, Vanderson Rocha
    British Journal of Haematology.2020; 188(6): 831.     CrossRef
  • Scientific Advances and the Evolution of Diagnosis, Subclassification and Treatment of Lymphoma
    Judith A. Ferry
    Archives of Medical Research.2020; 51(8): 749.     CrossRef
  • Development of diffuse large B-cell lymphoma from duodenal type follicular lymphoma: a retrospective study of 23 cases
    Masuho Saburi, Yoshiyuki Kondo, Masao Ogata, Yasuhiro Soga, Miyuki Abe, Kuniko Takano, Kazuhiro Kohno, Takayuki Nagai, Toshiyuki Nakayama
    International Journal of Hematology.2020; 112(5): 658.     CrossRef
  • Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma
    Kyu Hye Choi, Han Hee Lee, Seung-Eun Jung, Kyung-Sin Park, Joo-Hyun O, Young-Woo Jeon, Byung-Ock Choi, Seok-Goo Cho
    Radiation Oncology.2020;[Epub]     CrossRef
  • 11,894 View
  • 269 Download
  • 13 Web of Science
  • 15 Crossref
Close layer
Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study
Danbee Kang, Juhee Cho, Im Ryung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2018;50(4):1051-1063.   Published online November 9, 2017
DOI: https://doi.org/10.4143/crt.2017.207
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We evaluated health-related quality of life (HRQOL) in long-term survivors of indolent and aggressive non-Hodgkin lymphoma (NHL).
Materials and Methods
TheHRQOLwas assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) at diagnosis in NHL patients between 2008 and 2011, and follow-up evaluation was conducted from June 2014 to February 2015 using EORTC QLQ-C30 and the quality of life in cancer survivors (QOL-CS) questionnaire. We used linear mixed models to compare changes in HRQOL between indolent and aggressive NHL over time.
Results
The HRQOL of long-term survivors with aggressive NHL improved to the similar level of indolent NHL during the follow-up survey. However, survivors of NHL were found to fear the probability of relapse and second malignancy, and the degree of fear was not different between survivors with aggressive stage I/II or III/IV NHL (p > 0.05). Furthermore, a half of survivors reported impaired sense of psychosocial well-being regardless of aggressiveness and stage during follow-up survey. More than 65% of survivors thought they did not receive sufficient support from others, and patients who had financial difficulties at diagnosis were more frequently associated with suffering from insufficient support. Impaired physical and cognitive functioning at diagnosis was significantly associated with lack of life purpose in long-term survivors.
Conclusion
The HRQOL of aggressive NHL survivors improved to a similar level to that of indolent NHL. However, the majority of survivors still had fear of relapse, and psychosocial well-being remained unmet needs.

Citations

Citations to this article as recorded by  
  • Attenuated adiponectin, omentin, increased interleukin-6 and tumor necrosis factor-alpha levels with altered cognition and depression in non-Hodgkin lymphoma patients: A case-control study
    Meghavi Kathpalia, Pinki Mishra, Afsha Majid, Mohd. Ashif Khan, Anurag Sharma, Dinesh Bhurani, Nidhi
    Journal of Neuroimmunology.2024; 392: 578372.     CrossRef
  • Quality of life and late therapy effects in pediatric non‐Hodgkin lymphoma survivors: Insights from a single‐institution study
    Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad
    Pediatric Blood & Cancer.2024;[Epub]     CrossRef
  • Willingness to pay per quality-adjusted life year of Non-Hodgkin Lymphoma patients in Vietnam
    Phan Gia Huy, Pham Xuan Dung, Dang The Thap, Nguyen Tran Nhu Y
    Tạp Chí Khoa học Trường Đại học Quốc tế Hồng Bàng.2024; : 11.     CrossRef
  • Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
    Sohee Park, Ju Hwan Kim, Songhee Kim, Jisu Kang, Seoyoung Moon, Seok Jin Kim, Ju-Young Shin
    Blood Cancer Journal.2023;[Epub]     CrossRef
  • Factors associated with long-term functional and psychosocial outcomes in patients with non-Hodgkin lymphoma
    Bhasker Amatya, Michael Dickinson , Fary Khan
    Journal of Rehabilitation Medicine.2023; 55: jrm004816.     CrossRef
  • Experiences of and preferences for self-management among low grade non-Hodgkin's lymphoma survivors: A qualitative interview study
    Nickola D. Pallin, Mairead O'Connor, Alannah Gannon, John Browne, Mary R. Cahill, Derville O'Shea
    European Journal of Oncology Nursing.2023; 66: 102378.     CrossRef
  • Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study
    Stephane Kroudia Wasse, Morgane Mounier, Emerline Assogba, Cédric Rossi, Johan Adnet, Sophie Gauthier, Stephanie Girard, Kueshivi Midodji Atsou, Tienhan Sandrine Dabakuyo-Yonli, Marc Maynadie
    Cancers.2023; 15(15): 3885.     CrossRef
  • Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
    Leo I. Gordon, Fei Fei Liu, Julia Braverman, Daanish Hoda, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, Lily Peng, Shien Guo, Ling Shi, Alison Sehgal
    Haematologica.2023; 109(3): 857.     CrossRef
  • Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma
    Susan Ellis, Rhonda F. Brown, Einar B. Thorsteinsson, Kenneth I. Pakenham, Colin Perrott
    Psychology, Health & Medicine.2022; 27(8): 1649.     CrossRef
  • Pre‐treatment health‐related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience
    Åsa Lindberg, Christian Winther Eskelund, Alexandra Albertsson‐Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Christian Hartmann Geisler, Mats Jerkeman
    Hematological Oncology.2022; 40(1): 23.     CrossRef
  • Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study
    Amsalu Degu, Ermias Mergia Terefe, Eliab Seroney Some, Gobezie T Tegegne
    Cancer Management and Research.2022; Volume 14: 1525.     CrossRef
  • Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors
    Vanessa Boland, Amanda Drury, Greg Sheaf, Anne‐Marie Brady
    Psycho-Oncology.2022; 31(7): 1076.     CrossRef
  • The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
    Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, Louis S. Constine, Shahrukh K. Hashmi
    American Journal of Hematology.2022; 97(12): 1627.     CrossRef
  • Unmet Needs and Quality of Life of Colorectal Cancer Survivors Immediately after Treatment Ends and 5 Years
    Hyedan Kim, Eunsook Wi, Mi Hwa Jang, Sung Hee Jo, Hye Kyung Kim
    Asian Oncology Nursing.2022; 22(3): 145.     CrossRef
  • Trajectories of symptom severity predicts quality of life change in newly diagnosis lymphoma survivors: An initial study
    Chih‐Jung Wu, Yu‐Chi Chen, Li‐Yuan Bai, Tzeon‐Jye Chiou, Kuan‐Chia Lin, Ya‐Jung Wang
    European Journal of Cancer Care.2022;[Epub]     CrossRef
  • Exploring health-related quality of life among non-Hodgkin’s lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand
    Pichitra Lekdamrongkul, Kanaungnit Pongthavornkamol, Alex Molassiotis, Aurawamon Sriyuktasuth, Noppadol Siritanaratkul, Natkamol Chansatitporn
    Supportive Care in Cancer.2021; 29(11): 6511.     CrossRef
  • Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
    Choi Eunsook, Park Sunhee
    Clinical Journal of Nursing Care and Practice.2021; 5(1): 015.     CrossRef
  • Coping strategies among patients with malignant lymphoma– a qualitative study from the perspectives of Swedish patients
    Stinne Glasdam, Charlotta Bjerström, Cecilia Engberg de Carvalho
    European Journal of Oncology Nursing.2020; 44: 101693.     CrossRef
  • Impact of fear of cancer recurrence on survival among lymphoma patients
    Seok Jin Kim, Danbee Kang, Im Ryung Kim, Sang Eun Yoon, Won Seog Kim, Phyllis N. Butow, Eliseo Guallar, Juhee Cho
    Psycho-Oncology.2020; 29(2): 364.     CrossRef
  • Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
    Andrew Davies, Peter Trask, Judit Demeter, Axel Florschütz, Mathias Hänel, Tomohiro Kinoshita, Ruth Pettengell, Hang Quach, Stephen Robinson, Shalal Sadullah, Juan-Manuel Sancho, Miklos Udvardy, Mathias Witzens-Harig, Andrea Knapp, Wenxin Liu
    Annals of Hematology.2020; 99(12): 2837.     CrossRef
  • Quality of Life and Impact of Cancer: Differences in Rural and Nonrural Non‐Hodgkin's Lymphoma Survivors
    Devon Noonan, Matthew LeBlanc, Cherie Conley, Habtamu Benecha, Ashley Leak‐Bryant, Kellen Peter, Sheryl Zimmerman, Deborah Mayer, Sophia Smith
    The Journal of Rural Health.2020; 36(4): 536.     CrossRef
  • Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study
    Francesco Pallotti, Marianna Pelloni, Fabiana Faja, Silvia Di Chiano, Alice Di Rocco, Andrea Lenzi, Francesco Lombardo, Donatella Paoli
    Human Reproduction.2020;[Epub]     CrossRef
  • Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea
    Tran Thi Xuan Mai, Jin Hyuk Choi, Myung Kyung Lee, Yoon Jung Chang, So-Youn Jung, Hyunsoon Cho, Eun Sook Lee
    Cancer Research and Treatment.2019; 51(4): 1600.     CrossRef
  • 17,494 View
  • 426 Download
  • 21 Web of Science
  • 23 Crossref
Close layer
Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma
Ga-In Lee, Dongryul Oh, Won Seog Kim, Seok Jin Kim, Young Hyeh Ko, Kyung In Woo, Yoon-Duck Kim, Yong Chan Ahn
Cancer Res Treat. 2018;50(2):575-581.   Published online June 16, 2017
DOI: https://doi.org/10.4143/crt.2017.182
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the clinical features and the long-term outcomes of primary conjunctival marginal zone B-cell lymphoma (MZBCL) patients who were treated with radiation therapy (RT).
Materials and Methods
Retrospective data of 79 patients with 121 primary conjunctival MZBCL lesions were collected from January 1, 2001 till June 30, 2014. All lesions were treated by local RT (26 Gy) with patient-specific customized lens-shielding device.
Results
The current Korean patients’ cohort showed younger median age at diagnosis (38 years), great female preponderance (78.5%) and more frequent bilateral involvement (53.2%) than the previous studies. Following 26 Gy’s RT, excellent clinical outcomes were achieved: 5-year rates of overall survival, local relapse-free survival, and contralateral relapse-free survival were 100%, 98.1%, and 91.5%, respectively. Two patients (2.5%) developed local relapse and five (6.3%) developed relapse at initially uninvolved contralateral conjunctiva with median interval of 52.9 months, and late adverse events of grade 2 and 3 occurred in seven (8.8%) and two (2.5%) patients, respectively.
Conclusion
26 Gy’s RT was highly effective and safe, with the use of lens-shielding device, in treating patients with primary conjunctival MZBCL.

Citations

Citations to this article as recorded by  
  • Deintensification of radiation dose to 20 Gy for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma
    Jaeha Lee, Si Yeol Song, Young Seob Shin, Sung-Woo Kim, Ye Jin Yoo, Ji Hyeon Joo, Ho-Seok Sa, Dok Hyun Yoon, Sang-wook Lee
    Leukemia & Lymphoma.2025; : 1.     CrossRef
  • Iatrogenic Ocular Surface Complications After Surgery for Ocular and Adnexal Tumors
    Maria Angela Romeo, Andrea Taloni, Massimiliano Borselli, Alessandra Di Maria, Alessandra Mancini, Vincenzo Mollace, Giovanna Carnovale-Scalzo, Vincenzo Scorcia, Giuseppe Giannaccare
    Cancers.2025; 17(9): 1384.     CrossRef
  • Clinicopathologic features of conjunctival MALT lymphomas refractory to radiation therapy
    Yuka Suimon, Satoru Kase, Rumiko Kinoshita, Susumu Ishida
    Canadian Journal of Ophthalmology.2024; 59(5): e501.     CrossRef
  • Long‐term outcomes of patients with conjunctival extranodal marginal zone lymphoma
    Eduardo Edelman Saul, Juan Pablo Alderuccio, Isildinha M. Reis, Wei Zhao, Sunil G. Iyer, Gregor Rodriguez, Amrita Desai, Jennifer R. Chapman, David T. Tse, Arnold M. Markoe, Derek M. Isrow, Izidore S. Lossos
    American Journal of Hematology.2023; 98(1): 148.     CrossRef
  • Conjunctival Lymphoma
    Lindsay A. McGrath, David A. Ryan, Sunil K. Warrier, Sarah E. Coupland, William J. Glasson
    Eye.2023; 37(5): 837.     CrossRef
  • Long‐term survival outcomes of patients with primary ocular adnexal MALT lymphoma: A large single‐center cohort study
    Yuanzheng Liang, Rui‐ying Fu, Xue‐lin Liu, Xin‐di Liu, Ying‐shi Piao, Jian‐min Ma, Liang Wang
    Cancer Medicine.2023; 12(3): 2514.     CrossRef
  • Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study
    Kentaro Mizuhara, Tsutomu Kobayashi, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Kazuho Shimura, Koichi Hirakawa, Nobuhiko Uoshima, Katsuya Wada, Eri Kawata, Reiko Isa, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Akiko Yoneda
    Cancer Medicine.2023; 12(3): 3134.     CrossRef
  • Apigenin and Exposure to Low Dose Gamma Radiation Ameliorate Acetic Acid-Induced Ulcerative Colitis in Rats
    Eman E. Shibrya, Rasha R. Rashed, Mai A. Abd El Fattah, Mona A. El-Ghazaly, Sanaa A. Kenawy
    Dose-Response.2023;[Epub]     CrossRef
  • Ultra-low-dose radiation treatment for early-stage ocular adnexal MALT lymphoma
    Min Joung Lee, Me Yeon Lee, Ji-Young Choe, Se Hyun Choi, Hyo Jung Kim
    European Journal of Ophthalmology.2022; 32(5): 3092.     CrossRef
  • Ultra-low dose external beam radiotherapy for presumed choroidal lymphoma: a case report
    Jeremy P. M. Flanagan, Michael Ng, Awet Z. Kibrom, Robin J. A. Filshie, Richard J. Stawell, Roderick F. O’Day
    Journal of Ophthalmic Inflammation and Infection.2022;[Epub]     CrossRef
  • One Case of Conjunctival MALT Lymphoma and Literature Review
    旭霞 李
    Advances in Clinical Medicine.2022; 12(08): 7586.     CrossRef
  • Ocular surface complications of local anticancer drugs for treatment of ocular tumors
    Jayoon Moon, Se Hyun Choi, Min Joung Lee, Dong Hyun Jo, Un Chul Park, Sun-Ok Yoon, Se Joon Woo, Joo Youn Oh
    The Ocular Surface.2021; 19: 16.     CrossRef
  • Ocular Oncology—Primary and Metastatic Malignancies
    Basil K. Williams, Maura Di Nicola
    Medical Clinics of North America.2021; 105(3): 531.     CrossRef
  • Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours
    Giuseppe Giannaccare, Federico Bernabei, Martina Angi, Marco Pellegrini, Antonio Maestri, Vito Romano, Vincenzo Scorcia, Pierre-Räphael Rothschild
    Cancers.2021; 13(8): 1933.     CrossRef
  • Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients
    Khaled Elsayad, Gabriele Reinartz, Michael Oertel, Stephan Rehn, Jens Eismann, Sergiu Scobioala, Hendrik Berssenbrügge, Nicole Eter, Carsten Weishaupt, Hartmut H. Schmidt, Birte Friedrichs, Inga Grünewald, Wolfgang Hartmann, Georg Lenz, Eva Wardelmann, No
    Strahlentherapie und Onkologie.2020; 196(2): 117.     CrossRef
  • Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
    Andrés J. M. Ferreri, Marianna Sassone, Elisabetta Miserocchi, Silvia Govi, Caterina Cecchetti, Matteo E. Corti, Silvia Mappa, Luca Arcaini, Francesco Zaja, Giuseppe Todeschini, Donato Mannina, Teresa Calimeri, Salvatore Perrone, Maurilio Ponzoni, Giulio
    Blood Advances.2020; 4(6): 1013.     CrossRef
  • Patterns of care for orbital marginal zone B‐cell lymphoma of mucosa‐associated lymphoid tissue in Korea throughout 2016: Results from a multicenter cross‐sectional cohort study (KROG 16–19)
    Jeongshim Lee, Dongryul Oh, Byung Ock Choi, Keun‐Yong Eom, Jong Hoon Lee, Jung Hoon Kim, Sang Wook Lee, Yang Kwon Suh, Chang‐Ok Suh
    Asia-Pacific Journal of Clinical Oncology.2019; 15(6): 358.     CrossRef
  • Classification, diagnosis, and management of conjunctival lymphoma
    Rebecca E. Tanenbaum, Anat Galor, Sander R. Dubovy, Carol L. Karp
    Eye and Vision.2019;[Epub]     CrossRef
  • Necrotizing Fasciitis: Low-Dose Radiotherapy as a Potential Adjunct Treatment
    Gaurav Dhawan, Rachna Kapoor, Asha Dhamija, Ravinder Singh, Bharat Monga, Edward J. Calabrese
    Dose-Response.2019; 17(3): 155932581987175.     CrossRef
  • Health Impacts of Low-Dose Ionizing Radiation: Current Scientific Debates and Regulatory Issues
    Alexander Vaiserman, Alexander Koliada, Oksana Zabuga, Yehoshua Socol
    Dose-Response.2018;[Epub]     CrossRef
  • 15,582 View
  • 249 Download
  • 19 Web of Science
  • 20 Crossref
Close layer
Validation of the Korean Version of the Quality of Life–Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors
Juhee Cho, Danbee Kang, Im Ryung Kim, Won Seog Kim, Betty Ferrell, Seok Jin Kim
Cancer Res Treat. 2018;50(1):204-211.   Published online March 30, 2017
DOI: https://doi.org/10.4143/crt.2017.091
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The objective of this study was to validate the Korean version of the Quality of Life–Cancer Survivors (QOL-CS-K) in a sample of lymphoma survivors.
Materials and Methods
We conducted a cross-sectional survey of lymphoma survivors who had survived for at least 24 months since diagnosis. Participants were recruited at the outpatient clinics and at a hospital event in a tertiary hospital in Seoul, Korea. Survivors were asked to complete the QOLCS-K and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) questionnaires. To determine test-retest reliability, a second questionnaire was sent to participants who completed the first questionnaire adequately. Exploratory factor analysis and Pearson’s correlations were used for evaluating reliability and validity of the QOL-CS-K.
Results
Among 257 survivors, 245 (95.3%) completed all questionnaires and had no missing data. The mean age of study participants was 52.2 years, 54.9% were men, and the mean time since diagnosis was 4.0±1.6 years. The Cronbach’s α for the overall QOL-CS-K was 0.90, and the α coefficients for each subscale ranged from 0.73 to 0.83. The test and retest reliability was 0.88. Moderate correlations were found between comparable subscales of the QOL-CS-K and subscales of the EORTC QLQ-C30 (r=0.51-0.55) except for the spiritual well-being subscale of the QOL-CS-K, which did not correlate with any of the EORTC QLQ-C30 subscales (–0.08 to 0.16).
Conclusion
The QOL-CS-K is a reliable and valid scale for measuring the QOL in long-term lymphoma survivors.

Citations

Citations to this article as recorded by  
  • Korean patients with hereditary cancer: a prospective multicentre cohort study protocol exploring psychosocial and health outcomes
    Jun-Kyu Kim, Mi-Ae Jang, Jong Eun Park, Dongju Won, Jung-Sook Ha, Kyoung-Bo Kim, Boyoung Park, Sun-Young Kong
    BMJ Open.2025; 15(2): e093905.     CrossRef
  • Measuring patient‐reported distress from breast magnetic resonance imaging: Development and validation of the MRI‐related distress scale (MRI‐DS)
    Danbee Kang, Sooyeon Kim, Jiyoon Han, Youngha Kim, Juhee Cho, Jeong Eon Lee, Eun Sook Ko
    Cancer Medicine.2024;[Epub]     CrossRef
  • Quality of life patient/cancer survivor version in Chinese cancer survivors: A validation study
    Hai-Ying Wang, Stephen Wai Hang Kwok, Xian-Liang Liu, Tao Wang, Daniel Bressington, Yushan Shen, Qing Zhang, Hou-Qiang Huang, Jing-Yu Tan
    Asia-Pacific Journal of Oncology Nursing.2023; 10(8): 100255.     CrossRef
  • Analysis of etiological factors of nursing diagnosis of impaired comfort in children and adolescents with cancer
    Tânia Alteniza Leandro, Viviane Martins da Silva, Marcos Venícios de Oliveira Lopes, Nayana Maria Gomes de Souza, Kiarelle Lourenço Penaforte, Emanuela Aparecida Teixeira Gueiros, Marisa Nascimento de Oliveira
    Journal of Advanced Nursing.2023; 79(10): 3913.     CrossRef
  • Prediction Model for Postoperative Quality of Life Among Breast Cancer Survivors Along the Survivorship Trajectory From Pretreatment to 5 Years: Machine Learning–Based Analysis
    Danbee Kang, Hyunsoo Kim, Juhee Cho, Zero Kim, Myungjin Chung, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Jai Min Ryu, Se Kyung Lee
    JMIR Public Health and Surveillance.2023; 9: e45212.     CrossRef
  • The early predictive value of frailty for health-related quality of life among elderly patients with cancer receiving curative chemotherapy
    Yi-Cheng Hu, Shih-Ying Chen, Wen-Chi Chou, Jen-Shi Chen, Li-Chueh Weng, Pei-Kwei Tsay, Woung-Ru Tang, Chong-Chi Chiu
    PLOS ONE.2023; 18(8): e0287320.     CrossRef
  • The effect of web‐based intervention programs on self‐management and symptom management in patients with lymphoma: A systematic review of randomized controlled trials
    Merve Gozde Sezgin, Hicran Bektas
    Japan Journal of Nursing Science.2022;[Epub]     CrossRef
  • Factors affecting the quality of life of gastric cancer survivors
    Jahyun Choi, Sanghee Kim, Mona Choi, Woo Jin Hyung
    Supportive Care in Cancer.2022; 30(4): 3215.     CrossRef
  • The effect of decision support systems on pain in patients with cancer: A systematic review and meta‐analysis of randomized controlled trials
    Merve Gozde Sezgin, Hicran Bektas
    Journal of Nursing Scholarship.2022; 54(5): 578.     CrossRef
  • Impact of objective financial burden and subjective financial distress on spiritual well-being and quality of life among working-age cancer survivors
    Danbee Kang, Ka Ryeong Bae, Jihyun Lim, Nayeon Kim, Sungkeun Shim, Sun Seog Kweon, Hwa Jeong Seo, Juhee Cho
    Supportive Care in Cancer.2022; 30(6): 4917.     CrossRef
  • Feasibility and potential effects of breathing exercise for chronic pain management in breast cancer survivors: study protocol of a phase II randomised controlled trial
    Haiying Wang, Jing-Yu (Benjamin) Tan, Tao Wang, Xian-Liang Liu, Daniel Bressington, Si-Lin Zheng, Hou-Qiang Huang
    BMJ Open.2022; 12(12): e064358.     CrossRef
  • Health-related quality of life after transoral robotic thyroidectomy in papillary thyroid carcinoma
    Chang Myeon Song, Hyang Sook Bang, Hyung Gu Kim, Hae Jin Park, Kyung Tae
    Surgery.2021; 170(1): 99.     CrossRef
  • Impact of fear of cancer recurrence on survival among lymphoma patients
    Seok Jin Kim, Danbee Kang, Im Ryung Kim, Sang Eun Yoon, Won Seog Kim, Phyllis N. Butow, Eliseo Guallar, Juhee Cho
    Psycho-Oncology.2020; 29(2): 364.     CrossRef
  • A return-to-work intervention protocol directed at cancer patients (self-assessment, tailored information & lifestyle management for returning to work among cancer patients, START): A multi-center, randomized controlled trial
    Ka Ryeong Bae, Danbee Kang, Jae Yoon Yi, Yeojin Ahn, Im-Ryung Kim, Sun-Seog Kweon, Jin Seok Ahn, Seok Jin Nam, Young Mog Shim, Mison Chun, Jaesung Heo, Juhee Cho
    Contemporary Clinical Trials Communications.2020; 19: 100633.     CrossRef
  • Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study
    Danbee Kang, Juhee Cho, Im Ryung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim
    Cancer Research and Treatment.2018; 50(4): 1051.     CrossRef
  • 9,682 View
  • 272 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
Chi Hoon Maeng, Young Hyeh Ko, Do Hoon Lim, Eun Suk Kang, Joon Young Choi, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2017;49(1):92-103.   Published online May 9, 2016
DOI: https://doi.org/10.4143/crt.2015.476
AbstractAbstract PDFPubReaderePub
Purpose
This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a part of the conditioning regimen in patients with mature T- and natural killer (NK)-cell lymphomas.
Materials and Methods
Patients who underwent ASCT in the upfront or salvage setting between January 2000 and December 2013 were analyzed. Patients were dichotomized according to the TBI group (n=38) and non-TBI group (n=60) based on the type of conditioning regimen for ASCT.
Results
Patients with responsive disease underwent upfront ASCT (TBI, n=16; non-TBI, n=29) whereas patients with refractory disease (TBI, n=9; non-TBI, n=12) or relapsed disease (TBI, n=13; non-TBI, n=19) underwent ASCT after salvage treatment. Hematologic and non-hematologic toxicities were manageable, and the median cumulative toxicity score according to Seattle criteria was estimated as 2 (range, 0 to 7) in both groups. No significant difference in 100-day mortality was observed between the TBI (13%, 5/38) and non-TBI (12%, 12/60) groups, and most deaths were related to disease progression. There was no difference in overall and progression-free survival; however, the TBI group showed a trend of better survival in upfront and salvage ASCT than the non-TBI group. However, patients with refractory disease showed the worst outcome regardless of the use of TBI. Patients who showed complete response before ASCT showed better progression-free survival than thosewho showed partial response.
Conclusion
TBI could be used as an effective part of conditioning for ASCT in patients with mature T- and NK-cell lymphomas.

Citations

Citations to this article as recorded by  
  • Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics
    Mümtaz Köksal, Jonathan Baumert, Danny Jazmati, Felix Schoroth, Stephan Garbe, David Koch, Davide Scafa, Gustavo R. Sarria, Christina Leitzen, Gregor Massoth, Achilles Delis, Annkristin Heine, Tobias Holderried, Peter Brossart, Thomas Müdder, Leonard C. S
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7007.     CrossRef
  • The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
    Hao Wang, Kristin N. Berger, Elizabeth L. Miller, Wei Fu, Larisa Broglie, Frederick D. Goldman, Heiko Konig, Su Jin Lim, Arthur S. Berg, Julie-An Talano, Melanie A. Comito, Sherif S. Farag, Jeffrey J. Pu
    Therapeutic Advances in Hematology.2023;[Epub]     CrossRef
  • Helical versus static approaches to delivering tomotherapy to the junctional target for patients taller than 135 cm undergoing total body irradiation
    Mümtaz Köksal, Jonathan Baumert, Felix Schoroth, Thomas Müdder, Davide Scafa, David Koch, Christina Leitzen, Gustavo R. Sarria, Leonard C. Schmeel, Frank A. Giordano
    European Journal of Medical Research.2022;[Epub]     CrossRef
  • National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG)
    Naoya Ishibashi, Toshinori Soejima, Hiroki Kawaguchi, Takeshi Akiba, Masatoshi Hasegawa, Kouichi Isobe, Hitoshi Ito, Michiko Imai, Yasuo Ejima, Masaharu Hata, Keisuke Sasai, Emiko Shimoda, Toshiya Maebayashi, Masahiko Oguchi, Tetsuo Akimoto
    Journal of Radiation Research.2018; 59(4): 477.     CrossRef
  • 10,342 View
  • 189 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism
Sung Hee Lim, Sook-young Woo, Seonwoo Kim, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2016;48(1):312-321.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.266
AbstractAbstract PDFPubReaderePub
Purpose
The risk factors for venous thromboembolism (VTE) in diffuse large B-cell lymphoma (DLBCL) are not clear although thrombosis can be associated with host status, tumor burden, and inflammatory activity. We assessed the effect of those factors on VTE in a cross-sectional study of patients enrolled in a prospective cohort study. Materials and Methods We analyzed the occurrence of VTE in 322 patients with newly diagnosed DLBCL who received rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) between 2008 and 2011. Serum levels of inflammatory cytokines were measured from serum samples archived at diagnosis.
Results
With a median follow-up duration of 41.9 months, VTE was documented in 34 patients (10.6%). A comparison of baseline characteristics indicated the group with VTE had higher percentage of old age, stage III/IV and extranodal involvements than the group without VTE (p < 0.05). Thus, the International Prognostic Index was significantly associated with VTE, but the Khorana score was not. A univariate competing risk factor analysis for VTE revealed that increased levels of inflammatory cytokines such as interleukin (IL)-6 and IL-10 were also associated with VTE (p < 0.05) in addition to host and tumor burden. However, a multivariate analysis showed that two host factors including age (≥ 60 years) and poor performance were independent risk factors for VTE. Conclusion Among potential risk factors for VTE including tumor burden and inflammatory activity, age and performance status had a strong impact on the occurrence of VTE in patients with DLBCL who received R-CHOP.

Citations

Citations to this article as recorded by  
  • Thromboinflammatory Biomarkers in Lymphomas: Linking Inflammation to Thrombosis Risk
    Emilija Živković, Olivera Mitrović-Ajtić, Tijana Subotički, Jelena Ivanović, Vladimir Otašević, Dragoslava Đikić, Miloš Diklić, Milica Vukotić, Teodora Dragojević, Dejana Stanisavljević, Darko Antić, Vladan P. Čokić
    International Journal of Molecular Sciences.2025; 26(5): 2058.     CrossRef
  • Assessment and prognostic significance of a serum cytokine panel in diffuse large B‑cell lymphoma
    Shufang Xie, Lifen Zhu, Lei Wang, Shibing Wang, Xiangmin Tong, Wanmao Ni
    Oncology Letters.2024;[Epub]     CrossRef
  • Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma
    Irene Sánchez Prieto, Isabel Gutiérrez Jomarrón, Celia Martínez Vázquez, Pedro Rodríguez Barquero, Paula Gili Herreros, Julio García-Suárez
    Journal of Thrombosis and Thrombolysis.2024; 57(6): 984.     CrossRef
  • Thrombosis risk prediction in lymphoma patients: A multi‐institutional, retrospective model development and validation study
    Shengling Ma, Jennifer La, Kaitlin N. Swinnerton, Danielle Guffey, Raka Bandyo, Giordana De Las Pozas, Katy Hanzelka, Xiangjun Xiao, Cristhiam M. Rojas‐Hernandez, Christopher I. Amos, Vipul Chitalia, Katya Ravid, Kelly W. Merriman, Christopher R. Flowers,
    American Journal of Hematology.2024; 99(7): 1230.     CrossRef
  • Cancer and thrombosis—platelets and anti-platelet drugs—
    Kenji YOKOYAMA
    Japanese Journal of Thrombosis and Hemostasis.2023; 34(5): 549.     CrossRef
  • Incidence of venous thromboembolism and predictive ability of age-adjusted international prognostic index for prediction of venous thromboembolism in Asian patients with diffuse large B-cell lymphoma
    Nonthakorn Hantrakun, Phichayut Phinyo, Adisak Tantiworawit, Ekarat Rattarittamrong, Chatree Chai-Adisaksopha, Thanawat Rattanathammethee, Sasinee Hantrakool, Pokpong Piriyakhuntorn, Teerachat Punnachet, Piangrawee Niprapan, Lalita Norasetthada
    Journal of Thrombosis and Thrombolysis.2023; 57(3): 473.     CrossRef
  • Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Population‐Based Retrospective Cohort Study
    Nader Hanna, Susan B. Brogly, Xuejiao Shelly Wei, Christopher M. Booth, Sulaiman Nanji
    World Journal of Surgery.2022; 46(1): 180.     CrossRef
  • Venous‐thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma
    Radhika Gangaraju, Elizabeth S. Davis, Smita Bhatia, Kelly M. Kenzik
    Cancer.2022; 128(12): 2348.     CrossRef
  • Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases
    S. V. Ignatiev, A. V. Lyanguzov, E. S. Fokina, N. A. Zorina, K. A. Vorobiev
    Oncohematology.2022; 17(2): 134.     CrossRef
  • Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study
    Maja Bech Juul, Jelena Jelicic, Pavithra Laxsen Anru, Henriette Engberg, Pernille Hammershøj Jensen, Helene Bjørg Kristensen, Joachim Baech, Michael Roost Clausen, Anne Ortved Gang, Lars Munksgaard, Tarec Christoffer El-Galaly, Henrik Frederiksen, Thomas
    Leukemia & Lymphoma.2022; 63(9): 2074.     CrossRef
  • Takotsubo Syndrome (TTS) in Onco-Hematologic Patients: Retrospective Analysis and Focus on the Correlation or Not With Anticancer Drugs. Case Reports and Review of the Literature
    Manlio Monti, Pietro Cortesi, Roberto Vespignani, Ilaria Bronico, Chiara Gallio, Michele Flospergher, Laura Matteucci, Giovanni Luca Frassineti
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis
    Silvia García Adrián, Adán Rodríguez González, Eva Martínez de Castro, Vanessa Pachón Olmos, Laura Ortega Morán, Purificación Martínez del Prado, Mercedes Salgado Fernández, José David Cumplido Burón, Ignacio García Escobar, Joaquina Martínez Galán, Ana I
    European Journal of Internal Medicine.2022; 105: 30.     CrossRef
  • Venous thromboembolic events in T-cell lymphoma patients: Incidence, risk factors and clinical features
    Yingxia Lan, Jinqiu Guan, Jia Zhu, Juan Wang, Mengzhen Li, Chengtao Sun, Feifei Sun, Junting Huang, Suying Lu, Yizhuo Zhang
    Leukemia Research.2021; 103: 106537.     CrossRef
  • Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review
    Akari Nishimura, Yoshiaki Ikeda
    YAKUGAKU ZASSHI.2021; 141(4): 611.     CrossRef
  • The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma
    Hikmat Abdel-Razeq, Mohammad Ma’koseh, Asem Mansour, Rayan Bater, Rula Amarin, Alaa Abufara, Khalid Halahleh, Mohammad Manassra, Mohammad Alrwashdeh, Mohammad Almomani, Mais Zmaily
    Clinical and Applied Thrombosis/Hemostasis.2021;[Epub]     CrossRef
  • Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
    J. R. Gonzalez-Porras, J. Mateo, V. Gonzalez-Calle, P. Marco, V. Garcia-Gutierrez, J. C. Reverter, R. Lecumberri
    Clinical and Translational Oncology.2021; 24(5): 770.     CrossRef
  • The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma
    Onur Kirkizlar, Tugcan Alp Kirkizlar, Elif Gulsum Umit, Ismail Asker, Mehmet Baysal, Volkan Bas, Sedanur Karaman Gulsaran, Ufuk Demirci, Ahmet Muzaffer Demir
    Clinical Lymphoma Myeloma and Leukemia.2020; 20(8): 542.     CrossRef
  • Prediction of survival in non-Hodgkin lymphoma based on markers of systemic inflammation, anemia, hypercoagulability, dyslipidemia, and Eastern Cooperative Oncology Group performance status
    Ivan Dzis, Oleksandra Tomashevska, Yevhen Dzis, Zoryana Korytko
    Acta Haematologica Polonica.2020; 51(1): 34.     CrossRef
  • Mechanisms and biomarkers of cancer-associated thrombosis
    Ann S. Kim, Alok A. Khorana, Keith R. McCrae
    Translational Research.2020; 225: 33.     CrossRef
  • Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
    Stefan Hohaus, Francesca Bartolomei, Annarosa Cuccaro, Elena Maiolo, Eleonora Alma, Francesco D’Alò, Silvia Bellesi, Elena Rossi, Valerio De Stefano
    Cancers.2020; 12(5): 1291.     CrossRef
  • Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis
    Knut A. Mosevoll, Silje Johansen, Øystein Wendelbo, Ina Nepstad, Øystein Bruserud, Håkon Reikvam
    Frontiers in Medicine.2018;[Epub]     CrossRef
  • Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice
    Joanna Rupa‐Matysek, Katarzyna Brzeźniakiewicz‐Janus, Lidia Gil, Zbigniew Krasiński, Mieczysław Komarnicki
    Cancer Medicine.2018; 7(7): 2868.     CrossRef
  • Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma
    Joanna Rupa-Matysek, Lidia Gil, Marta Barańska, Dominik Dytfeld, Mieczysław Komarnicki
    Oncotarget.2018; 9(30): 21190.     CrossRef
  • Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B‐cell lymphoma
    Joanna Rupa‐Matysek, Lidia Gil, Renata Kroll‐Balcerzak, Marta Barańska, Mieczysław Komarnicki
    Hematological Oncology.2017; 35(4): 456.     CrossRef
  • Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients
    Patrizia Ferroni, Fabio Massimo Zanzotto, Noemi Scarpato, Silvia Riondino, Umberto Nanni, Mario Roselli, Fiorella Guadagni
    Medical Decision Making.2017; 37(2): 234.     CrossRef
  • Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma
    Ina Hornemann Borg, Mette Dahl Bendtsen, Martin Bøgsted, Jakob Madsen, Marianne Tang Severinsen
    Leukemia & Lymphoma.2016; 57(12): 2771.     CrossRef
  • Risk of thromboembolism with lymphoma: myth or reality?
    Kate L. Burbury, Marliese Alexander, David A. Westerman
    Leukemia & Lymphoma.2016; 57(12): 2736.     CrossRef
  • 12,718 View
  • 103 Download
  • 26 Web of Science
  • 27 Crossref
Close layer
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
Silvia Park, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2015;47(3):448-457.   Published online November 3, 2014
DOI: https://doi.org/10.4143/crt.2014.034
AbstractAbstract PDFPubReaderePub
Purpose
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Although febrile neutropenia (FN) is the major toxicity of this regimen, non-neutropenic fever (NNF) becomes an emerging issue. Materials and Methods We analyzed clinical features and outcomes of febrile complications from 397 patients with newly diagnosed DLBCL who were registered in the prospective cohort study. They had completed R-CHOP between September 2008 and January 2013. Results Thirty-nine patients (9.8%) had NNF whereas 160 patients (40.3%) had FN. Among them, 24 patients (6.0%) had both during their treatment. Compared to frequent occurrence of initial FN after the first cycle (> 50% of total events), more than 80% of NNF cases occurred after the third cycle. Interstitial pneumonitis comprised the highest proportion of NNF cases (54.8%), although the causative organism was not identified in the majority of cases. Thus, pathogen was identified in a limited number of patients (n=9), and Pneumocystis jiroveci pneumonia (PJP) was the most common. Considering that interstitial pneumonitis without documented pathogen could be clinically diagnosed with PJP, the overall rate of PJP including probable cases was 4.5% (18 cases from 397 patients). The NNF-related mortality rate was 10.3% (four deaths from 39 patients with NNF) while the FN-related mortality rate was only 1.3%. Conclusion NNF was observed with incidence of 10% during R-CHOP treatment, and showed different clinical manifestations with respect to the time of initial episode and causes.

Citations

Citations to this article as recorded by  
  • Incidence and risk factors of severe infections in diffuse large B-cell lymphoma patients undergoing immunochemotherapy
    Haiqiu Zhao, Rong Su, Jie Luo, Lin Liu
    Annals of Hematology.2025;[Epub]     CrossRef
  • Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies
    Wailong Zou, Jia Zhang, Yulin Li, Zhe Zhang, Rui Yang, Yaxin Yan, Weihua Zhu, Feng Ma, Piping Jiang, Yumin Wang, Xinjun Zhang, Jichao Chen
    Annals of Hematology.2024;[Epub]     CrossRef
  • The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study
    Ioannis Baltas, Konstantinos Kavallieros, Giannis Konstantinou, Eirini Koutoumanou, Malick M Gibani, Mark Gilchrist, Frances Davies, Jiri Pavlu
    JAC-Antimicrobial Resistance.2023;[Epub]     CrossRef
  • Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL
    Akihiro Ohmoto, Shigeo Fuji
    Blood Reviews.2021; 46: 100738.     CrossRef
  • Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature
    Aleksandra Gładyś, Sylwia Kozak, Kamil Wdowiak, Mateusz Winder, Jerzy Chudek
    World Journal of Clinical Cases.2021; 9(3): 748.     CrossRef
  • Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction‐based diagnosis in patients receiving bendamustine
    Mikhaila L. Rice, Jason N. Barreto, Carrie A. Thompson, Kristin C. Mara, Pritish K. Tosh, Andrew H. Limper
    Cancer Medicine.2021; 10(15): 5120.     CrossRef
  • Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival
    Wen Wei, Yajie Zhu, Jianning Tang, Chuan Xu, Jiman Li, Shuya He, Zhihui Zhang, Ping Wu, Lei Luo, Qin Guo, Fang Li, Yuanrong Ren, Sisi Yu, Renqin Li, Li Li
    Leukemia Research.2021; 111: 106688.     CrossRef
  • A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the fina
    Sang Eun Yoon, Seok Jin Kim, Dok Hyun Yoon, Youngil Koh, Yeung-Chul Mun, Young Rok Do, Yoon Seok Choi, Deok Hwan Yang, Min Kyoung Kim, Gyeong-Won Lee, Cheolwon Suh, Young Hyeh Ko, Won Seog Kim
    Annals of Hematology.2020; 99(6): 1283.     CrossRef
  • Prognostic significance of infectious episodes occurring during first‐line therapy for diffuse large B‐cell lymphoma ‐ A nationwide cohort study
    Michael R. Clausen, Sinna P. Ulrichsen, Maja B. Juul, Christian B. Poulsen, Brian Iversen, Per T. Pedersen, Jakob Madsen, Robert S. Pedersen, Pär L. Josefsson, Jette S. Gørløv, Mette Nørgaard, Francesco d'Amore
    Hematological Oncology.2020; 38(3): 318.     CrossRef
  • Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494)
    Vicki A. Morrison, Edie A. Weller, Thomas M. Habermann, Shuli Li, Richard I. Fisher, Bruce D. Cheson, Bruce A. Peterson
    Leukemia & Lymphoma.2017; 58(8): 1814.     CrossRef
  • Pneumocystispneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy
    Se Yoon Park, Mi Young Kim, Won Jin Choi, Dok Hyun Yoon, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Cheolwon Suh, Jun Hee Woo, Sung-Han Kim
    Medical Mycology.2016; : myw095.     CrossRef
  • Neoplastic fever in patients with bone and soft tissue sarcoma
    Tomoki Nakamura, Akihiko Matsumine, Takao Matsubara, Kunihiro Asanuma, Akihiro Sudo
    Molecular and Clinical Oncology.2016; 5(5): 631.     CrossRef
  • Can mortality of cancer patients with fever and neutropenia be improved?
    Karin A. Thursky, Leon J. Worth
    Current Opinion in Infectious Diseases.2015; 28(6): 505.     CrossRef
  • 12,769 View
  • 113 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh
Cancer Res Treat. 2015;47(2):173-181.   Published online October 28, 2014
DOI: https://doi.org/10.4143/crt.2014.055
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by  
  • Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
    Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
    Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
    Cancer Medicine.2019; 8(3): 874.     CrossRef
  • ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
    Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
    Leukemia & Lymphoma.2019; 60(10): 2532.     CrossRef
  • Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
    Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
    International Journal of Hematology.2018; 107(4): 395.     CrossRef
  • Recent advances in treating extra-ocular lymphomas
    Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
    Expert Review of Ophthalmology.2018; 13(4): 205.     CrossRef
  • The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
    Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
    Blood Research.2017; 52(1): 3.     CrossRef
  • Primary lymphomas in the gastrointestinal tract
    Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
    Journal of Digestive Diseases.2015; 16(4): 169.     CrossRef
  • 16,131 View
  • 145 Download
  • 10 Web of Science
  • 7 Crossref
Close layer
Case Reports
Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein
Jung Min Ha, Eun Kim, Woo Joo Lee, Ji-Won Hwang, Sehyo Yune, Young Hyeh Ko, Joon Young Choi, Seok Jin Kim, Won Seog Kim
Cancer Res Treat. 2014;46(3):307-311.   Published online July 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.3.307
AbstractAbstract PDFPubReaderePub
Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma. It usually presents with nonspecific symptoms, such as fever, rather than with overt lymphadenopathy. Reports of hypercalcemia, as the initial presentation of IVLBCL, are limited in the literature, despite it being a well-known complication of various solid cancers. We present a 68-year-old male with severe hypercalcemia and increased levels of serum parathyroid hormone-related protein. He was diagnosed with IVLBCL, involving the bone marrow and spleen, and was successfully treated with rituximab-containing chemotherapy. A few previous case reports have shown hypercalcemia in patients with IVLBCL. Much like our case, previous cases with hypercalcemia had advanced diseases, including bone marrow invasion. Although it was an extremely rare manifestation of IVLBCL, we suggest that IVLBCL should be a part of the differential diagnosis in patients with unexplained hypercalcemia. Therefore, an active work-up might be recommended, including positron emission tomography/ computed tomography scan and bone marrow examination, which may be useful for early diagnosis.

Citations

Citations to this article as recorded by  
  • A case of intravascular large B-cell lymphoma complicated by hypercalcaemia
    Masahiro Yabe, Takashi Abe, Saori Yamaga, Seiga Ozaki, Katsuhiro Tomiyama, Hideki Hashidate
    European Journal of Case Reports in Internal Medicine.2025;[Epub]     CrossRef
  • Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature
    Yingying Han, Qingjiao Li, Dan Wang, Lushan Peng, Tao Huang, Chunlin Ou, Keda Yang, Junpu Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma
    Chae Hong Lim, Sang Eun Yoon, Won Seog Kim, Kyung-Han Lee, Seok Jin Kim
    Cancer Management and Research.2021; Volume 13: 7289.     CrossRef
  • Missed diagnosis of lymphoma presenting with humoral hypercalcemia of malignancy due to cessation of oncological workup after negative computed tomography scans
    Ellery Altshuler, Mahmoud Aryan, William King, Rolando Otero
    BMJ Case Reports.2021; 14(12): e246669.     CrossRef
  • The spectrum of lymphoproliferative disorders in endocrine organs: from histology to molecular genetics
    Silvia Uccella, Francesca Magnoli, Cristina Amaglio, Fausto Sessa, Stefano La Rosa
    Diagnostic Histopathology.2019; 25(5): 166.     CrossRef
  • Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
    Kosei Matsue, Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Daisuke Miura, Kengo Takeuchi
    British Journal of Haematology.2019; 187(3): 328.     CrossRef
  • Klinische und pathologische Charakteristika intravaskulärer Lymphome
    L. Abraham, H. Kreipe, P. Raab, K. Hussein
    Der Pathologe.2018; 39(3): 242.     CrossRef
  • Primary Bone Marrow B-Cell Lymphoma Undetected by Multiple Imaging Modalities That Initially Presented with Hypercalcemia
    Jin Sae Yoo, Juwon Kim, Hyeong Ju Kwon, Jung Soo Lim
    Case Reports in Endocrinology.2018; 2018: 1.     CrossRef
  • Klinische und pathologische Charakteristika intravaskulärer Lymphome
    Lara Abraham, Hans H. Kreipe, Peter Raab, Kais Hussein
    Wiener klinisches Magazin.2018; 21(5): 206.     CrossRef
  • 12,659 View
  • 67 Download
  • 7 Web of Science
  • 9 Crossref
Close layer
Orbital Infiltration as the First Site of Relapse of Primary Testicular T-cell Lymphoma
Hyun Jung Jun, Won Seog Kim, Ji Hyun Yang, Seong Yoon Yi, Young H. Ko, Jeeyun Lee, Chul Won Jung, Se Woong Kang, Keunchil Park
Cancer Res Treat. 2007;39(1):40-43.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.40
AbstractAbstract PDFPubReaderePub

A 43-year-old male presented with a painless left testicular mass. The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u). According to the Ann Arbor staging system, his initial stage was III because of the right nasopharyngeal involvement. After first-line chemotherapy with four courses of the CHOP regimen and this was followed by involved-field radiotherapy, he achieved complete remission. Two months later, disease recurred to the left ciliary body of the left eye without evidence of involvement at other sites. Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding. Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

Citations

Citations to this article as recorded by  
  • Relapse of Ocular Lymphoma following Primary Testicular Diffuse Large B-cell Lymphoma
    Hye Ji Kwon, Joo Yong Lee
    Journal of Retina.2023; 8(1): 58.     CrossRef
  • Chronic lymphocytic leukemia and concurrent seminoma in the same testis
    Kosuke Miyai, Fumihisa Kumazawa, Kimiya Sato, Hitoshi Tsuda
    Journal of Pathology and Translational Medicine.2022; 56(1): 48.     CrossRef
  • Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas
    Natalia Zing, Thais Fischer, Massimo Federico, Carlos Chiattone, Andrés J.M. Ferreri
    Critical Reviews in Oncology/Hematology.2021; 167: 103496.     CrossRef
  • Primary testicular T-lymphoblastic lymphoma in a child
    Yongren Wang, Jian Li, Yongjun Fang
    Medicine.2020; 99(26): e20861.     CrossRef
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified and Concurrent Seminoma in Testis
    Junichi Kitagawa, Naoe Goto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Takeshi Hara, Katsuyoshi Takata, Yasuharu Sato, Tadashi Yoshino, Hisashi Tsurumi
    Journal of Clinical and Experimental Hematopathology.2015; 55(3): 169.     CrossRef
  • Primary testicular lymphoma
    Chan Y. Cheah, Andrew Wirth, John F. Seymour
    Blood.2014; 123(4): 486.     CrossRef
  • Testicular lymphoma, intraocular (Vitreoretinal) lymphoma, and brain lymphoma: Involvement of three immunoprivileged sites in one patient
    Jacob Pe'er, Jacob M. Rowe, Shahar Frenkel, Eldad J. Dann
    American Journal of Hematology.2010; 85(8): 631.     CrossRef
  • 10,286 View
  • 68 Download
  • 7 Crossref
Close layer
Original Articles
Mouse Orthotopic Lung Cancer Model Induced by PC14PE6
Zheng Yun Cui, Jin Seok Ahn, Jee Yun Lee, Won Seog Kim, Ho Yeong Lim, Hyun Jung Jeon, Soo Won Suh, Jin Hoon Kim, Won Ho Kong, Ji Min Kang, Do Hyun Nam, Keunchil Park
Cancer Res Treat. 2006;38(4):234-239.   Published online December 31, 2006
DOI: https://doi.org/10.4143/crt.2006.38.4.234
AbstractAbstract PDFPubReaderePub
Purpose

This study was undertaken to investigate in detail the xenograft mouse orthotopic lung cancer model induced by PC14PE6 adenocarcinoma cells.

Materials and Methods

Three cell doses (0.5×106; 1×106; 2×106) of PC14PE6 cells were injected into the lungs of male BALB/c nude mice by the intrathoracic injection method. The lung and other organs, including brain, liver, spleen, kidney, muscle, adrenal gland, and lymph node on knee, were removed and stained with H/E to detect the presence of tumor cells.

Results

The reliable tumorigenicity time in the PC14PE6 adenocarcinoma cell-inoculated BALB/c nude mouse was 10 days after intrathoracic injection. The average life span of the three groups after inoculation was 14 days in the 2×106 cells inoculum group; 25 days in the 1×106 cells inoculum group; and 32 days in the 0.5×106 cells inoculum group. The PC14PE6 adenocarcinoma cells induced orthotopic lung cancer limited within the thorax.

Conclusions

This orthotopic lung cancer model is an efficient cancer model with easy inoculation methods, rapid and high tumorigenicity, and simple monitoring methods for metastasis.

Citations

Citations to this article as recorded by  
  • Protocol for the establishment of murine orthotopic lung tumors and the assessment of contralateral pulmonal metastasis by flow cytometry
    Gregor Zaun, Siyang Liu, Maximilian Webendörfer, Abubakar Wani, Diego Rodriguez, Douglas R. Green, Halime Kalkavan
    STAR Protocols.2025; 6(2): 103793.     CrossRef
  • Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor
    Natalia Khromova, Maria Vasileva, Vera Dugina, Dmitry Kudlay, Peter Chumakov, Sergei Boichuk, Pavel Kopnin
    Cancers.2024; 16(6): 1123.     CrossRef
  • Immuno-PET Imaging of EGFR with 64Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts
    Nasim Sarrami, Melinda Wuest, Igor Moura de Paiva, Samantha Leier, Afsaneh Lavasanifar, Frank Wuest
    Molecular Pharmaceutics.2024; 21(11): 5797.     CrossRef
  • Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand
    M. Isabel Acuña, Ana R. Rubio, Marta Martínez-Alonso, Natalia Busto, Ana María Rodríguez, Nerea Davila-Ferreira, Carl Smythe, Gustavo Espino, Begoña García, Fernando Domínguez
    Cancers.2022; 15(1): 107.     CrossRef
  • Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment
    Ulrich Jarry, Mégane Bostoën, Raphaël Pineau, Laura Chaillot, Valentine Mennessier, Pierre Montagne, Emilie Motte, Marjorie Gournay, Arnaud Le Goff, Thierry Guillaudeux, Rémy Pedeux
    BMC Cancer.2021;[Epub]     CrossRef
  • Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach
    Hor-Yue Tan, Venice Wing-Tung Ho, Yau-Tuen Chan, Cheng Zhang, Ning Wang, Wen Xia, Yibin Feng
    Pharmacological Research.2020; 155: 104415.     CrossRef
  • Metastatic Spread from Abdominal Tumor Cells to Parathymic Lymph Nodes
    Gábor Király, Zoltán Hargitai, Ilona Kovács, Gábor Szemán-Nagy, István Juhász, Gáspár Bánfalvi
    Pathology & Oncology Research.2019; 25(2): 625.     CrossRef
  • LPP inhibits collective cell migration during lung cancer dissemination
    S Kuriyama, M Yoshida, S Yano, N Aiba, T Kohno, Y Minamiya, A Goto, M Tanaka
    Oncogene.2016; 35(8): 952.     CrossRef
  • Docetaxel-loaded polyglutamic acid-PEG nanocapsules for the treatment of metastatic cancer
    Erea Borrajo, Raquel Abellan-Pose, Atenea Soto, Marcos Garcia-Fuentes, Noemi Csaba, Maria J. Alonso, Anxo Vidal
    Journal of Controlled Release.2016; 238: 263.     CrossRef
  • Targeting p300 Addiction inCBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation ofMYCExpression
    Hideaki Ogiwara, Mariko Sasaki, Takafumi Mitachi, Takahiro Oike, Saito Higuchi, Yuichi Tominaga, Takashi Kohno
    Cancer Discovery.2016; 6(4): 430.     CrossRef
  • Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice
    T. Jaroensong, Y. Endo, S.‐J. Lee, A. Kamida, M. Mochizuki, R. Nishimura, N. Sasaki, T. Nakagawa
    Veterinary and Comparative Oncology.2012; 10(4): 274.     CrossRef
  • A Novel Bioluminescence Orthotopic Mouse Model for Advanced Lung Cancer
    Bo Li, Artour Torossian, Wenyan Li, Stephen Schleicher, Kathy Niu, Nicholas J. Giacalone, Sung June Kim, Heidi Chen, Adriana Gonzalez, Luigi Moretti, Bo Lu
    Radiation Research.2011; 176(4): 486.     CrossRef
  • Small Azurin Derived Peptide Targets Ephrin Receptors for Radiotherapy
    Ewa D. Micewicz, Chun-Ling Jung, Dorthe Schaue, Hai Luong, William H. McBride, Piotr Ruchala
    International Journal of Peptide Research and Therapeutics.2011; 17(3): 247.     CrossRef
  • The Incidence Rate and Severity of Orthotopic Lung Cancer in an Animal Model Depends on the Number of A549 Cells and Transplantation Period
    Jinsoo Lee, Young-Ah Han, Hyo-Seon Yang, Jeong-Ah Song, Young-Su Yang, Soonjin Kwon, Min-Sung Kang, Kyuhong Lee, Jeong-Doo Heo, Kyu-Hyuk Cho, Chang Woo Song
    Laboratory Animal Research.2010; 26(4): 369.     CrossRef
  • Tumorigenesis after Injection of Lung Cancer Cell Line (SW-900 G IV) into the Pleural Cavity of Nude Mice
    Eok-Sung Park, Song-Myung Kim, Jong-In Kim
    The Korean Journal of Thoracic and Cardiovascular Surgery.2010; 43(6): 588.     CrossRef
  • Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
    Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park
    Cancer Research and Treatment.2009; 41(2): 80.     CrossRef
  • 16,638 View
  • 127 Download
  • 16 Crossref
Close layer
Treatment Outcome of Limited Stage Hodgkin's Disease
Jung Hun Kang, Yong Chan Ahn, Won Seog Kim, Won Ki Kang
Cancer Res Treat. 2005;37(1):31-36.   Published online February 28, 2005
DOI: https://doi.org/10.4143/crt.2005.37.1.31
AbstractAbstract PDFPubReaderePub
Purpose

The 10-year overall survival rate following conventional treatments for patients with limited-stage Hodgkin's disease (HD) exceeds 90%. However, the clinical features and treatment outcome of HD in Korea have not been extensively characterized due to its low incidence. In this study, we attempted to analyze the treatment outcome of different modalities in limited stage HD patients.

Materials and Methods

Twenty one Hodgkin's disease patients, referred to the Samsung Medical Center between January 1997 and December 2003, were enrolled in this study. Limited stage Hodgkin's disease was subdivided into low and high risk groups. All evaluable patients received treatment.

Results

There were 13 and 8 patients in the low and high risk groups, respectively. Eighteen patients (86%) obtained complete response (CR) and 3 patients (14%) achieved an undetermined complete response (CRu). Fourteen (67%), 4 (19%) and 3 (14%) cases received combination chemotherapy, radiotherapy alone and chemotherapy alone, respectively. Four cases relapsed and 2 obtained a second CR. The 5-year overall and disease-free survival rates were 90 and 72%, respectively, for all patients. The median follow-up duration was 31 months. There was no difference in disease free survival (DFS) between the low and high risk groups. Although 12 cases had neutropenia greater than grade III, none experienced neutropenic fever.

Conclusion

The treatment outcome of limited-stage HD was excellent, regardless to the initial treatment modality.

  • 7,943 View
  • 42 Download
Close layer
Case Reports
Three Cases of Synchronous Solid Tumor and Multiple Myeloma
Sang Hoon Ji, Joon Oh Park, Jeeyun Lee, Mi Jung Oh, Do Hyoung Lim, Byeong-Bae Park, Keun Woo Park, Se-Hoon Lee, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H Lee, Keunchil Park
Cancer Res Treat. 2004;36(5):338-340.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.338
AbstractAbstract PDFPubReaderePub

The association between a multiple myeloma and a secondary solid tumor is not well established. Some reports showed an increased risk of secondary solid neoplasms in multiple myeloma patients, but others have not. Three cases of the synchronous occurrence of multiple myelomas and solid tumors, namely, a small cell carcinoma of the lung, an adenocarcinoma of the colon and a squamous carcinoma of the pyriform sinus were experienced at our hospital. Therefore, herein is reported the clinical courses and treatment results. The stage of multiple myeloma was Durie-Salmon stage I in all of three cases; therefore, the solid tumors were treated as a primary target because the prognosis of early stage multiple myeloma is generally better than that of advanced solid tumor, while a smoldering or stage I myeloma do not need primary therapy until progression of the multiple myeloma. Two patients died of their solid tumors, but one patient is alive.

Citations

Citations to this article as recorded by  
  • Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
    Koki Tamai, Hajime Hirose, Yo Akazawa, Yukihiro Yoshikawa, Masatoshi Nomura, Hiroshi Takeyama, Masahiro Tokunaga, Mitsuyoshi Tei, Shu Okamura, Yusuke Akamaru
    Surgical Case Reports.2024;[Epub]     CrossRef
  • The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia
    M. F. Petrukhnova, O. O. Voronkova, O. E. Buyanova, O. N. Antyufeeva, A. E. Kamalova, M. V. Kozhevnikova, I. S. Ilgisonis, Yu. N. Belenkov
    Meditsinskiy sovet = Medical Council.2024; (9): 100.     CrossRef
  • Synchronous multiple myeloma and lung adenocarcinoma: A clinical series
    Fang Ye, Huan Wang, Ningning Li, Aijun Liu, Wenming Chen
    Indian Journal of Pathology and Microbiology.2024; 67(2): 390.     CrossRef
  • Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature
    Huan-Huan Dong, Jing Li, Lin Kang, Qiang Wei, Yan Li
    Oncology Letters.2022;[Epub]     CrossRef
  • Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: A case report
    Naoto Ujiie, Yoshitaka Enomoto, Naruhito Takido, Yasushi Kawaharada, Masashi Zuguchi, Yosuke Kubota
    International Journal of Surgery Case Reports.2021; 81: 105834.     CrossRef
  • Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma
    Wenli Zuo, Xinghu Zhu, Jingke Yang, Zhenyang Mei, Mei Deng, Quande Lin, Yongping Song, Qingsong Yin
    Medicine.2017; 96(1): e5787.     CrossRef
  • Drastic Response to Nivolumab in a Case Demonstrating a Rapid Recurrence of Pulmonary Pleomorphic Carcinoma That Developed After Chemotherapy for Comorbid Myeloma Kidney
    Aya Yamamoto, Takashi Iwata, Koji Hashimoto
    Haigan.2017; 57(7): 849.     CrossRef
  • Challenges in managing a patient with multiple primary malignancies
    Nataliya Mar, David Askin, Jerry George, Colette Spaccavento, Robert Graham, Lynn Ratner
    Community Oncology.2012; 9(12): 377.     CrossRef
  • ¿Asociación entre colangiocarcinoma y mieloma múltiple?
    Laura Gómez-Escolar Viejo, Gema Soler Sala, Vanessa Castaño Giraldo, José María Palazón Azorín, Miguel Pérez-Mateo Regadera
    Gastroenterología y Hepatología.2008; 31(6): 402.     CrossRef
  • Synchronous Presentation of Multiple Myeloma and Lung Cancer
    Rishu Agarwal, Ritu Gupta, Archana Bhaskar, Atul Sharma, Sanjay Thulkar, Lalit Kumar
    Journal of Clinical Oncology.2008; 26(35): 5814.     CrossRef
  • 10,405 View
  • 54 Download
  • 10 Crossref
Close layer
Esophageal Squamous Cell Carcinoma Recurring as a Solitary Renal Mass
Do Hyoung Lim, Young-Hyuck Im, Sang Hoon Ji, Byeong-Bae Park, Mi Jung Oh, Jeeyun Lee, Keun Woo Park, Se-Hoon Lee, Joon-Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Mark H Lee, Kwanmien Kim, Young Mog Shim, Keunchil Park
Cancer Res Treat. 2004;36(4):271-274.   Published online August 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.4.271
AbstractAbstract PDFPubReaderePub

Herein, a case of solitary, unilateral renal metastasis in a patient with curatively resected thoracic esophageal carcinoma, who achieved a pathological complete remission after neoadjuvant concurrent chemoradiotherapy, is reported. The kidney is the 4th or 5th most common visceral metastasis site of a primary esophageal carcinoma. More than 50% of renal metastases typically show bilateral involvement. Solitary, unilateral renal metastasis is extremely rare. Renal metastases from a primary esophageal carcinoma are usually latent and its diagnosis is very unusual in a live patient. The solitary renal metastasis in this case was not accompanied by metastases to other sites. The value of a nephrectomy in solitary renal metastasis of esophageal cancer is not known due to the rarity of such cases. A nephrectomy could be justified in limited situations, such as with uncertainty of histological diagnosis, severe life-threatening hematuria, which cannot be controlled by embolization, or solitary renal metastasis with a long disease-free interval.

Citations

Citations to this article as recorded by  
  • Rapidly Rising Serum Creatinine in a Patient With Colorectal Adenocarcinoma and Eosinophilia: A Quiz
    Athiphat Banjongjit, Vorachai Ratanatharathorn, Piyanut Mahanupap, Winyou Mitarnun
    American Journal of Kidney Diseases.2024; 83(2): A14.     CrossRef
  • Esophageal squamous cell carcinoma metastases to kidney and renal hilar lymph nodes through epithelial-mesenchymal transition: a case report and literature review
    Nai-Jun Fan
    American Journal of Translational Research.2024; 16(5): 1825.     CrossRef
  • Secondary Tumors of the Kidney: A Comprehensive Clinicopathologic Analysis
    Faisal Saeed, Adeboye O. Osunkoya
    Advances in Anatomic Pathology.2022; 29(4): 241.     CrossRef
  • Surgery for metachronous oligometastatic esophageal cancer: Is there enough evidence?
    Dimitrios Schizas, Michail Vailas, Maria Sotiropoulou, Ioannis A. Ziogas, Konstantinos S. Mylonas, Ioannis Katsaros, Alkistis Kapelouzou, Theodore Liakakos
    Cirugía Española.2021; 99(7): 490.     CrossRef
  • Surgery for metachronous oligometastatic esophageal cancer: Is there enough evidence?
    Dimitrios Schizas, Michail Vailas, Maria Sotiropoulou, Ioannis A. Ziogas, Konstantinos S. Mylonas, Ioannis Katsaros, Alkistis Kapelouzou, Theodore Liakakos
    Cirugía Española (English Edition).2021; 99(7): 490.     CrossRef
  • The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature
    Dimitrios Schizas, Ioannis I. Lazaridis, Demetrios Moris, Aikaterini Mastoraki, Lazaros-Dimitrios Lazaridis, Diamantis I. Tsilimigras, Nikolaos Charalampakis, Theodore Liakakos
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • Esophageal Cancer with Solitary Renal Metastasis Treated with Multidisciplinary Therapy: A Case Report and Mini Review of the Literature
    Kyoung Sik Nam, Kyoungwon Jung, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Jae Hyun Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(1): 39.     CrossRef
  • Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review
    Osama Shaheen, Abdulaziz Ghibour, Bayan Alsaid
    Gastroenterology Research and Practice.2017; 2017: 1.     CrossRef
  • FDG PET/CT in 2 Cases of Renal Metastasis From Esophageal Squamous Cell Carcinoma
    Qian Zhao, Aisheng Dong, Bo Yang, Yang Wang, Changjing Zuo
    Clinical Nuclear Medicine.2017; 42(11): 896.     CrossRef
  • Solitary renal metastasis of esophageal squamous cell carcinoma mimicking primary renal neoplasm – A case report and literature review
    Kai-Po Chang, Chi-Ping Huang, Han Chang
    BioMedicine.2016;[Epub]     CrossRef
  • Unilateral renal metastases after definitive chemoradiation in squamous cell carcinoma of esophagus: A case report and review literature
    Kapil Dev, Jaiprakash Gurawalia, Sandeep Nayak, Balu Sadasivan
    Asian Journal of Oncology.2016; 02: 046.     CrossRef
  • Renal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review
    Yan Sun, Xinmin Yu, Yiping Zhang
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • Esophageal Adenocarcinoma with Solitary Renal Metastasis
    Thomas D. Willson, Matthew J. Blecha, Mark M. Connolly, Francis J. Podbielski
    Journal of Gastrointestinal Cancer.2013; 44(3): 351.     CrossRef
  • Synchronous Squamous Cell Carcinomas of the Esophagus and Renal Pelvis
    Te-Chun Hsieh, Yu-Chin Wu, Shung-Shung Sun, I-Ping Chiang, Chun-Fan Yang, Kuo-Yang Yen, Chia-Hung Kao
    Clinical Nuclear Medicine.2011; 36(11): e171.     CrossRef
  • 9,874 View
  • 62 Download
  • 14 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP